171 results on '"Wolinsky SM"'
Search Results
2. Preservation of tetherin and CD4 counter-activities in circulating Vpu alleles despite extensive sequence variation within HIV-1 infected individuals
- Author
-
Pickering S, Huxe9 S, Kim EY, Reddy S, Wolinsky SM, and Neil SJ.
- Published
- 2014
3. Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load
- Author
-
McLaren, PJ, Coulonges, C, Bartha, I, Lenz, TL, Deutsch, AJ, Bashirova, A, Buchbinder, S, Carrington, MN, Cossarizza, A, Dalmau, J, DE LUCA, ANDREA, Goedert, JJ, Gurdasani, D, Haas, DW, Herbeck, JT, Johnson, EO, Kirk, GD, Lambotte, O, Luo, M, Mallal, S, van Manen, D, Martinez-Picado, J, Meyer, L, Miro, JM, Mullins, JI, Obel, N, Poli, G, Sandhu, MS, Schuitemaker, H, Shea, PR, Theodorou, I, Walker, BD, Weintrob, AC, Winkler, CA, Wolinsky, SM, Raychaudhuri, S, Goldstein, DB, Telenti, A, de Bakker, PIW, Zagury, J, Fellay, J, McLaren, PJ, Coulonges, C, Bartha, I, Lenz, TL, Deutsch, AJ, Bashirova, A, Buchbinder, S, Carrington, MN, Cossarizza, A, Dalmau, J, DE LUCA, ANDREA, Goedert, JJ, Gurdasani, D, Haas, DW, Herbeck, JT, Johnson, EO, Kirk, GD, Lambotte, O, Luo, M, Mallal, S, van Manen, D, Martinez-Picado, J, Meyer, L, Miro, JM, Mullins, JI, Obel, N, Poli, G, Sandhu, MS, Schuitemaker, H, Shea, PR, Theodorou, I, Walker, BD, Weintrob, AC, Winkler, CA, Wolinsky, SM, Raychaudhuri, S, Goldstein, DB, Telenti, A, de Bakker, PIW, Zagury, J, and Fellay, J
- Published
- 2015
4. Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study
- Author
-
Study Group on Death Rates at High CD4 Count in Antiretroviral Naive Patients, Lodwick, Rk, Sabin, Ca, Porter, K, Ledergerber, B, van Sighem, A, Cozzi Lepri, A, Khaykin, P, Mocroft, A, Jacobson, L, De Wit, S, Obel, N, Castagna, A, Wasmuth, Jc, Gill, J, Klein, Mb, Gange, S, Riera, M, Mussini, C, Gutiérrez, F, Touloumi, G, Carrieri, P, Guest, Jl, Brockmeyer, Nh, Collaborators: Antoniadou A, Phillips A. N., Gargalianos Kakolyris, P, Katsarou, O, Kordossis, T, Lazanas, M, Panos, G, Paparizos, V, Paraskevis, D, Petrikkos, G, Sambatakou, H, Skoutelis, A, Pantazis, N, Bakoyannis, G, Gioukari, V, de Wolf, F, Bezemer, Do, Gras, La, Kesselring, Am, van Sighem AI, Smit, C, Zhang, S, Zaheri, S, Prins, Jm, Schreij, G, Bravenboer, B, van der Ende ME, Kauffmann, Rh, ten Kate RW, Kroon, Fp, Bronsveld, W, Vriesendorp, R, van Houte, D, ten Napel CH, Brinkman, K, van Eeden, A, Mulder, Jw, Juttmann, Jr, Veenstra, J, Koopmans, Pp, Sprenger, Hg, Hoepelman, Im, Danner, Sa, Richter, C, Tanis, Aa, Clumeck, N, Delforge, M, Necsoi, C, Demeester, R, Gennotte, Af, Gerard, M, Guillaume, Mp, Hermans, P, Kabeya, K, Konopnicki, D, Martin, C, Libois, A, Payen, Mc, Semaille, P, Van Laethem, Y, Del Amo, J, Meyer, L, Bucher, Hc, Chêne, G, Pillay, D, Prins, M, Rosinska, M, Sabin, C, Lodi, S, Coughlin, K, Walker, S, Babiker, A, Bucher, H, de Luca, A, Fisher, M, Muga, R, Fätkenheuer, G, Rockstroh, J, Vehreschild, J, Hertenstein, C, Berenguer, J, del Amo, J, García, F, Labarga, P, Moreno, S, Angeles Muñoz, M, Caro Murillo AM, Sobrino, P, Pérez Cachafeiro, S, Jarrín, I, Alejos, B, García, I, Gómez Sirvent, J, Soriano, V, Pulido, F, Iribarren, J, Masiá, M, Vidal, F, Sanz, J, Blanco, Ja, Sola, J, Gerstoft, J, Kronborg, G, Røge, B, Larsen, Cs, Pedersen, G, Laursen, Al, Nielsen, L, Jensen, J, Babacan, E, Bickel, M, Bodtländer, A, Brodt, Hr, Carlebach, A, Gute, P, Haberl, A, Helm, E, Klauke, S, Knecht, G, Lennemann, T, Locher, L, Lutz, T, Mösch, M, Müller, A, Nisius, G, Staszewski, S, Stephan, C, Stürmer, M, von Hentig, N, Wolf, T, Rimland, D, Moanna, A, Moorfield, M, Dorsey, M, Desilva, Ke, Schlueter Wirtz, S, Mindley, R, Dozier, R, Robinson, Y, Brown, P, Moroni, M, Angarano, G, Antinori, A, Carosi, G, Cauda, R, d'Arminio Monforte, A, Di Perri, G, Galli, M, Ghinelli, G, Iardino, R, Ippolito, G, Lazzarin, A, Mazzotta, F, Perno, Cf, Viale, Pl, Von Schlosser, F, Ammassari, A, Balotta, C, Bonfanti, P, Capobianchi, Mr, Ceccherini Silberstein, F, De Luca, A, Gervasoni, C, Girardi, E, Lo Caputo, S, Maggiolo, F, Murri, R, Puoti, M, Torti, Carlo, Salpietro, S, Marangione, M, Galli, L, Gianotti, N, Cossarini, F, Spagnuolo, V, Arendt, G, Esser, S, Jäger, H, Schwarze, S, Stoll, M, Wolf, H, Jansen, K, Michalik, C, Skaletz Rorowski, A, Königs, C, Gingelmaier, A, Margolick, Jb, Jacobson, Lp, Phair, Jp, Wolinsky, Sm, Detels, R, Rinaldo, Cr, Boirot, C, Bouhnik, Ad, Carrieri, Mp, Cassuto, Jp, Chesney, M, Cohen, J, Dellamonica, P, Dujardin, P, Gallais, H, Gastaut, Ja, Kurkdji, P, Lepeu, G, Mechali, D, Moatti, Jp, Moreau, J, Nègre, M, Obadia, Y, Poizot Martin, I, Pradier, C, Préau, M, Rey, D, Roux, P, Rouzioux, C, Sobel, A, Spire, B, Trémolières, F, Villes, V, Vincent, E, Vlahov, D, Borghi, V, Casabona, J, Miró, Jm, Gatell, Jm, López Dieguez Puerta, M, Tural, C, Clotet, B, Podzamczer, D, Ferrer, E, Murillas, J, Segura, F, Navarro, G, Force, L, Vilaró, J, Masabeu, A, Guadarrama, M, Betancourt, Aj, Romero, A, Agustí, C, Battegay, M, Bernasconi, E, Böni, J, Bürgisser, P, Calmy, A, Cavassini, M, Dubs, R, Egger, M, Elzi, L, Fischer, M, Flepp, M, Fontana, A, Francioli, P, Furrer, H, Fux, Ca, Gorgievski, M, Günthard, Hf, Hirsch, Hh, Hirschel, B, Hösli, I, Kahlert, C, Kaiser, L, Karrer, U, Kind, C, Klimkait, T, Martinetti, G, Martinez, B, Müller, N, Nadal, D, Paccaud, F, Pantaleo, G, Rauch, A, Regenass, S, Rickenbach, M, Rudin, C, Schmid, P, Schultze, D, Schöni, F, Schüpbach, J, Speck, R, Taffé, P, Telenti, A, Trkola, A, Vernazza, P, Weber, R, Yerly, S, Ainsworth, J, Anderson, J, Delpech, V, Dunn, D, Easterbrook, P, Gazzard, B, Gilson, R, Gompels, M, Hill, T, Johnson, M, Leen, C, Nelson, M, Orkin, C, Palfreeman, A, Phillips, A, Post, F, Schwenk, A, Walsh, J, Bansi, L, Huntington, S, Glabay, A, Anastos, K, Minkoff, H, Young, M, Greenblatt, R, Levine, A, Cohen, M, and Gange, S.
- Published
- 2010
5. Copy number variation of KIR genes influences HIV-1 control
- Author
-
Pelak, K, Need, AC, Fellay, J, Shianna, KV, Feng, S, Urban, TJ, Ge, D, de Luca, A, Martinez-Picado, J, Wolinsky, SM, Martinson, JJ, Jamieson, BD, Bream, JH, Martin, MP, Borrow, P, Letvin, NL, McMichael, AJ, Haynes, BF, Telenti, A, Carrington, M, Goldstein, DB, Alter, G, Pelak, K, Need, AC, Fellay, J, Shianna, KV, Feng, S, Urban, TJ, Ge, D, de Luca, A, Martinez-Picado, J, Wolinsky, SM, Martinson, JJ, Jamieson, BD, Bream, JH, Martin, MP, Borrow, P, Letvin, NL, McMichael, AJ, Haynes, BF, Telenti, A, Carrington, M, Goldstein, DB, and Alter, G
- Abstract
A genome-wide screen for large structural variants showed that a copy number variant (CNV) in the region encoding killer cell immunoglobulin-like receptors (KIR) associates with HIV-1 control as measured by plasma viral load at set point in individuals of European ancestry. This CNV encompasses the KIR3DL1-KIR3DS1 locus, encoding receptors that interact with specific HLA-Bw4 molecules to regulate the activation of lymphocyte subsets including natural killer (NK) cells. We quantified the number of copies of KIR3DS1 and KIR3DL1 in a large HIV-1 positive cohort, and showed that an increase in KIR3DS1 count associates with a lower viral set point if its putative ligand is present (p = 0.00028), as does an increase in KIR3DL1 count in the presence of KIR3DS1 and appropriate ligands for both receptors (p = 0.0015). We further provide functional data that demonstrate that NK cells from individuals with multiple copies of KIR3DL1, in the presence of KIR3DS1 and the appropriate ligands, inhibit HIV-1 replication more robustly, and associated with a significant expansion in the frequency of KIR3DS1+, but not KIR3DL1+, NK cells in their peripheral blood. Our results suggest that the relative amounts of these activating and inhibitory KIR play a role in regulating the peripheral expansion of highly antiviral KIR3DS1+ NK cells, which may determine differences in HIV-1 control following infection. © 2011 Pelak et al.
- Published
- 2011
6. Common genetic variation and the control of HIV-1 in humans
- Author
-
Fellay, J, Ge, D, Shianna, KV, Colombo, S, Ledergerber, B, Cirulli, ET, Urban, TJ, Zhang, K, Gumbs, CE, Smith, JP, Castagna, A, Cozzi-Lepri, A, De Luca, A, Easterbrook, P, Günthard, HF, Mallal, S, Mussini, C, Dalmau, J, Martinez-Picado, J, Miro, JM, Obel, N, Wolinsky, SM, Martinson, JJ, Detels, R, Margolick, JB, Jacobson, LP, Descombes, P, Antonarakis, SE, Beckmann, JS, O'Brien, SJ, Letvin, NL, McMichael, AJ, Haynes, BF, Carrington, M, Feng, S, Telenti, A, Goldstein, DB, Fellay, J, Ge, D, Shianna, KV, Colombo, S, Ledergerber, B, Cirulli, ET, Urban, TJ, Zhang, K, Gumbs, CE, Smith, JP, Castagna, A, Cozzi-Lepri, A, De Luca, A, Easterbrook, P, Günthard, HF, Mallal, S, Mussini, C, Dalmau, J, Martinez-Picado, J, Miro, JM, Obel, N, Wolinsky, SM, Martinson, JJ, Detels, R, Margolick, JB, Jacobson, LP, Descombes, P, Antonarakis, SE, Beckmann, JS, O'Brien, SJ, Letvin, NL, McMichael, AJ, Haynes, BF, Carrington, M, Feng, S, Telenti, A, and Goldstein, DB
- Abstract
To extend the understanding of host genetic determinants of HIV-1 control, we performed a genome-wide association study in a cohort of 2,554 infected Caucasian subjects. The study was powered to detect common genetic variants explaining down to 1.3% of the variability in viral load at set point. We provide overwhelming confirmation of three associations previously reported in a genome-wide study and show further independent effects of both common and rare variants in the Major Histocompatibility Complex region (MHC). We also examined the polymorphisms reported in previous candidate gene studies and fail to support a role for any variant outside of the MHC or the chemokine receptor cluster on chromosome 3. In addition, we evaluated functional variants, copy-number polymorphisms, epistatic interactions, and biological pathways. This study thus represents a comprehensive assessment of common human genetic variation in HIV-1 control in Caucasians.
- Published
- 2009
7. OA06-02. Monospecific expansion of SIVmac251 during acute infection masks multiple transmitted virus variants revealed during the chronic phase
- Author
-
Felber, BK, primary, Kim, E, additional, Pal, R, additional, Desrosiers, RC, additional, Wolinsky, SM, additional, and Pavlakis, GN, additional
- Published
- 2009
- Full Text
- View/download PDF
8. Targeting the Human CD3γ Gene Promoter By HIV-1 and HTLV-1: Two Distinct Mechanisms Involving A Transcriptional Regulatory Element and Chromatin Remodeling
- Author
-
Willard-Gallo, KE, primary, Badran, BM, additional, Akl, H, additional, Ravoet, M, additional, Dorbrita, G, additional, Manfouo-Foutsop, G, additional, Equeter, C, additional, Burny, A, additional, Kunstman, K, additional, Stanton, J, additional, and Wolinsky, SM, additional
- Published
- 2005
- Full Text
- View/download PDF
9. Retrovirology.
- Author
-
Wolinsky SM
- Published
- 1994
- Full Text
- View/download PDF
10. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy.
- Author
-
Furtado MR, Callaway DS, Phair JP, Kunstman KJ, Stanton JL, Macken CA, Perelson AS, and Wolinsky SM
- Published
- 1999
11. Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load
- Author
-
Andrea De Luca, Aaron J. Deutsch, Deepti Gurdasani, David W. Haas, Jean-François Zagury, Susan Buchbinder, Simon Mallal, Manjinder S. Sandhu, Steven M. Wolinsky, Cédric Coulonges, Laurence Meyer, Paul I.W. de Bakker, James I. Mullins, Daniëlle van Manen, Andrea Cossarizza, José M. Miró, Amy C. Weintrob, Tobias L. Lenz, Judith Dalmau, Olivier Lambotte, Niels Obel, James J. Goedert, Mary Carrington, Ma Luo, Arman Bashirova, David Goldstein, Gregory D. Kirk, Joshua T. Herbeck, Amalio Telenti, Paul J. McLaren, Patrick R. Shea, Javier Martinez-Picado, Cheryl A. Winkler, Bruce D. Walker, Istvan Bartha, Jacques Fellay, Ioannis Theodorou, Hanneke Schuitemaker, Guido Poli, Eric O. Johnson, Soumya Raychaudhuri, Other departments, AII - Amsterdam institute for Infection and Immunity, Experimental Immunology, Mclaren, Pj, Coulonges, C, Bartha, I, Lenz, Tl, Deutsch, Aj, Bashirova, A, Buchbinder, S, Carrington, Mn, Cossarizza, A, Dalmau, J, De Luca, A, Goedert, Jj, Gurdasani, D, Haas, Dw, Herbeck, Jt, Johnson, Eo, Kirk, Gd, Lambotte, O, Luo, M, Mallal, S, van Manen, D, Martinez Picado, J, Meyer, L, Miro, Jm, Mullins, Ji, Obel, N, Poli, Guido, Sandhu, M, Schuitemaker, H, Shea, Pr, Theodorou, I, Walker, Bd, Weintrob, Ac, Winkler, Ca, Wolinsky, Sm, Raychaudhuri, S, Goldstein, Db, Telenti, A, de Bakker, Pi, Zagury, Jf, and Fellay, J.
- Subjects
Adult ,Receptors, CCR5 ,infectious disease ,Inheritance Patterns ,Genome-wide association study ,Peptide binding ,Human leukocyte antigen ,Biology ,heritability ,Research Support ,Settore MED/17 - MALATTIE INFETTIVE ,Polymorphism, Single Nucleotide ,Genomics ,GWAS ,Heritability ,HIV-1 control ,Infectious disease ,Journal Article ,genomics ,Humans ,Genetic Predisposition to Disease ,Allele ,Amino Acids ,Non-U.S. Gov't ,Genotyping ,Alleles ,Genetic association ,Genetics ,Multidisciplinary ,Research Support, Non-U.S. Gov't ,Haplotype ,Viral Load ,Biological Sciences ,Physical Chromosome Mapping ,HLA-B Antigens ,Host-Pathogen Interactions ,HIV-1 ,Chromosomes, Human, Pair 3 ,Viral load ,Genome-Wide Association Study - Abstract
Previous genome-wide association studies (GWAS) of HIV-1-infected populations have been underpowered to detect common variants with moderate impact on disease outcome and have not assessed the phenotypic variance explained by genome-wide additive effects. By combining the majority of available genome-wide genotyping data in HIV-infected populations, we tested for association between similar to 8 million variants and viral load (HIV RNA copies per milliliter of plasma) in 6,315 individuals of European ancestry. The strongest signal of association was observed in the HLA class I region that was fully explained by independent effects mapping to five variable amino acid positions in the peptide binding grooves of the HLA-B and HLA-A proteins. We observed a second genome-wide significant association signal in the chemokine (C-C motif) receptor (CCR) gene cluster on chromosome 3. Conditional analysis showed that this signal could not be fully attributed to the known protective CCR5 Delta 32 allele and the risk P1 haplotype, suggesting further causal variants in this region. Heritability analysis demonstrated that common human genetic variation-mostly in the HLA and CCR5 regions-explains 25% of the variability in viral load. This study suggests that analyses in non-European populations and of variant classes not assessed by GWAS should be priorities for the field going forward.
- Published
- 2015
12. Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons
- Author
-
Rotger, M, Glass, Tr, Junier, T, Lundgren, J, Neaton, Jd, Poloni, Es, van 't Wout AB, Lubomirov, R, Colombo, S, Martinez, R, Rauch, A, Günthard, Hf, Neuhaus, J, Wentworth, D, van Manen, D, Gras, La, Schuitemaker, H, Albini, L, Torti, C, Jacobson, Lp, Li, X, Kingsley, La, Carli, F, Guaraldi, G, Ford, Es, Sereti, I, Hadigan, C, Martinez, E, Arnedo, M, Egaña-Gorroño, L, Gatell, Jm, Law, M, Bendall, C, Petoumenos, K, Rockstroh, J, Wasmuth, Jc, Kabamba, K, Delforge, M, De Wit, S, Berger, F, Mauss, S, de Paz Sierra, M, Losso, M, Belloso, Wh, Leyes, M, Campins, A, Mondi, A, De Luca, A, Bernardino, I, Barriuso-Iglesias, M, Torrecilla-Rodriguez, A, Gonzalez-Garcia, J, Arribas, Jr, Fanti, I, Gel, S, Puig, J, Negredo, E, Gutierrez, M, Domingo, P, Fischer, J, Fätkenheuer, G, Alonso-Villaverde, C, Macken, A, Woo, J, Mcginty, T, Mallon, P, Mangili, A, Skinner, S, Wanke, Ca, Reiss, P, Weber, R, Bucher, Hc, Fellay, J, Telenti, A, Tarr, Pe, Vullo, V, Magnificent, Consortium, Insight, Swiss HIV Cohort Study, Mastroianni, C, MAGNIFICENT Consortium, Swiss HIV Cohort Study, INSIGHT, Rotger, M., Glass, TR., Lubomirov, R., Bucher, HC., Telenti, A., Tarr, PE., Junier, T., Poloni, ES., Fellay, J., Colombo, S., Martinez, R., Rauch, A., Weber, R., Günthard, HF., Neuhaus, J., Wentworth, D., Lundgren, J., Neaton, JD., van Manen, D., Gras, AL., Schuitemaker, H., van Wout AB., Reiss, P., Albini, L., Torti, C., Jacobson, LP., Li, X., Kingsley, LA., Carli, F., Guaraldi, G., Ford, ES., Sereti, I., Hadigan, C., Martinez, E., Arnedo-Valero, M., Egaña-Gorroño, L., Gatell, JM., Law, M., Bendall, C., Petoumenos, K., Rockstroh, J., Wasmuth, JC., Kabamba, K., Delforge, M., De Wit, S., Berger, F., Mauss, S., Sierra Mde, P., Losso, M., Belloso, WH., Leyes, M., Campins, A., Mondi, A., De Luca, A., Bernardino, I., Barriuso-Iglesias£££Mónica£££ M., Rodriguez, AT., Garcia, JG., Arribas, JR., Fanti, I., Gel, S., Puig, J., Negredo, E., Gutierrez, M., Domingo, P., Fischer, J., Fätkenheuer, G., Alonso-Villaverde, C., Macken, A., Woo, J., McGinty, T., Mallon, P., Mangili, A., Skinner, S., Wanke, CA., Aubert, V., Barth, J., Battegay, M., Bernasconi, E., Böni, J., Burton-Jeangros, C., Calmy, A., Cavassini, M., Egger, M., Elzi, L., Fehr, J., Francioli, P., Furrer, H., Fux, CA., Gorgievski, M., Günthard, H., Haerry, D., Hasse, B., Hirsch, HH., Hirschel, B., Hösli, I., Kahlert, C., Kaiser, L., Keiser, O., Kind, C., Klimkait, T., Kovari, H., Ledergerber, B., Martinetti, G., Martinez de Tejada, B., Metzner, K., Müller, N., Nadal, D., Pantaleo, G., Regenass, S., Rickenbach, M., Rudin, C., Schmid, P., Schultze, D., Schöni-Affolter, F., Schüpbach, J., Speck, R., Taffé, P., Tarr, P., Trkola, A., Vernazza, P., Prins, YS., Kuijpers, TW., Scherpbier, HJ., Boer, K., van der Meer JT., Wit, FW., Godfried, MH., van der Poll, T., Nellen, FJ., Lange, JM., Geerlings, SE., van Vugt, M., Vrouenraets, SM., Pajkrt, D., Bos, JC., van der Valk, M., Schreij, G., Lowe, S., Lashof, AO., Pronk, MJ., Bravenboer, B., van der Ende ME., de Vries-Sluijs TE., Schurink, CA., van der Feltz, M., Nouwen, JL., Gelinck, LB., Verbon, A., Rijnders, BJ., van de Ven-de Ruiter ED., Slobbe, L., Haag, D., Kauffmann, RH., Schippers, EF., Groeneveld, PH., Alleman, MA., Bouwhuis, JW., ten Kate RW., Soetekouw, R., Kroon, FP., van den Broek PJ., van Dissel JT., Arend, SM., van Nieuwkoop, C., de Boer MJ., Jolink, H., den Hollander JG., Pogany, K., Bronsveld, W., Kortmann, W., van Twillert, G., van Houte DP., Polée, MB., van Vonderen MG., ten Napel CH., Kootstra, GJ., Brinkman, K., Blok, WL., Frissen, PH., Schouten, WE., van den Berk GE., Juttmann, JR., van Kasteren ME., Brouwer, AE., Mulder, JW., van Gorp EC., Smit, PM., Weijer, S., van Eeden, A., Verhagen, DW., Sprenger, HG., Doedens, R., Scholvinck, EH., van Assen, S., Stek, CJ., Hoepelman, IM., Mudrikova, T., Schneider, MM., Jaspers, CA., Ellerbroek, PM., Peters, EJ., Maarschalk-Ellerbroek, LJ., Oosterheert, JJ., Arends, JE., Wassenberg, MW., van der Hilst JC., Richter, C., van der Berg JP., Gisolf, EH., Margolick, JB., Plankey, M., Crain, B., Dobs, A., Farzadegan, H., Gallant, J., Johnson-Hill, L., Sacktor, N., Selnes, O., Shepard, J., Thio, C., Phair, JP., Wolinsky, SM., Badri, S., Conover, C., O'Gorman, M., Ostrow, D., Palella, F., Ragin, A., Detels, R., Martínez-Maza, O., Aronow, A., Bolan, R., Breen, E., Butch, A., Fahey, J., Jamieson, B., Miller, EN., Oishi, J., Vinters, H., Visscher, BR., Wiley, D., Witt, M., Yang, O., Young, S., Zhang, ZF., Rinaldo, CR., Becker, JT., Cranston, RD., Martinson, JJ., Mellors, JW., Silvestre, AJ., Stall, RD., Muñoz, A., Abraham, A., Althoff, K., Cox, C., D'Souza, G., Gange, SJ., Golub, E., Schollenberger, J., Seaberg, EC., Su, S., Huebner, RE., Dominguez, G., Moroni, M., Angarano, G., Antinori, A., Carosi, G., Cauda, R., Monforte£££A d'Arminio£££ A., Di Perri, G., Galli, M., Iardino, R., Ippolito, G., Lazzarin, A., Perno, CF., Sagnelli, E., Viale, PL., Von Schlosser, F., d'Arminio Monforte, A., Ammassari, A., Andreoni, M., Balotta, C., Bonfanti, P., Bonora, S., Borderi, M., Capobianchi, MR., Castagna, A., Ceccherini-Silberstein, F., Cozzi-Lepri, A., Gargiulo, M., Gervasoni, C., Girardi, E., Lichtner, M., Lo Caputo, S., Madeddu, G., Maggiolo, F., Marcotullio, S., Monno, L., Murri, R., Mussini, C., Puoti, M., Formenti, T., Galli, L., Lorenzini, P., Montroni, M., Giacometti, A., Costantini, A., Riva, A., Tirelli, U., Martellotta, F., Ladisa, N., Lazzari, G., Verucchi, G., Castelli, F., Scalzini, A., Minardi, C., Bertelli, D., Quirino, T., Abeli, C., Manconi, PE., Piano, P., Vecchiet, J., Falasca, K., Carnevale, G., Lorenzotti, S., Sighinolfi, L., Segala, D., Leoncini, F., Mazzotta, F., Pozzi, M., Cassola, G., Viscoli, G., Viscoli, A., Piscopo, R., Mazzarello, G., Mastroianni, C., Belvisi, V., Caramma, I., Chiodera, A., Castelli, P., Rizzardini, G., Ridolfo, AL., Foschi, A., Salpietro, S., Galli, A., Bigoloni, A., Spagnuolo, V., Merli, S., Carenzi, L., Moioli, MC., Cicconi, P., Bisio, L., Gori, A., Lapadula, G., Abrescia, N., Chirianni, A., De Marco, M., Ferrari, C., Borghi, R., Baldelli, F., Belfiori, B., Parruti, G., Ursini, T., Magnani, G., Ursitti, MA., Narciso, P., Tozzi, V., Vullo, V., d'Avino, A., Zaccarelli, M., Gallo, L., Acinapura, R., Capozzi, M., Libertone, R., Trotta, MP., Tebano, G., Cattelan, AM., Mura, MS., Caramello, P., Orofino, GC., Sciandra, M., Raise, Ebo, F., Pellizzer, G., Manfrin, V., McManus, H., Wright, S., Moore, R., Edwards, S., Medische Microbiologie, RS: CAPHRI School for Public Health and Primary Care, AII - Amsterdam institute for Infection and Immunity, Experimental Immunology, Other departments, Graduate School, APH - Amsterdam Public Health, Global Health, Medical Microbiology and Infection Prevention, Paediatric Infectious Diseases / Rheumatology / Immunology, Other Research, Obstetrics and Gynaecology, Infectious diseases, General Internal Medicine, Center of Experimental and Molecular Medicine, University of Zurich, Tarr, Philip E, Rotger, M, Glass, T, Junier, T, Lundgren, J, Neaton, J, Poloni, E, Van 'T Wout, A, Lubomirov, R, Colombo, S, Martinez, R, Rauch, A, Günthard, H, Neuhaus, J, Wentworth, D, Van Manen, D, Gras, L, Schuitemaker, H, Albini, L, Torti, C, Jacobson, L, Li, X, Kingsley, L, Carli, F, Guaraldi, G, Ford, E, Sereti, I, Hadigan, C, Martinez, E, Arnedo, M, Egaña Gorroño, L, Gatell, J, Law, M, Bendall, C, Petoumenos, K, Rockstroh, J, Wasmuth, J, Kabamba, K, Delforge, M, De Wit, S, Berger, F, Mauss, S, De Paz Sierra, M, Losso, M, Belloso, W, Leyes, M, Campins, A, Mondi, A, De Luca, A, Bernardino, I, Barriuso Iglesias, M, Torrecilla Rodriguez, A, Gonzalez Garcia, J, Arribas, J, Fanti, I, Gel, S, Puig, J, Negredo, E, Gutierrez, M, Domingo, P, Fischer, J, Fätkenheuer, G, Alonso Villaverde, C, Macken, A, Woo, J, Mcginty, T, Mallon, P, Mangili, A, Skinner, S, Wanke, C, Reiss, P, Weber, R, Bucher, H, Fellay, J, Telenti, A, Tarr, P, Gori, A, Junier, Thomas, Poloni, Estella S., Rotger, Margalida, Glass, Tracy R., Junier, Thoma, Lundgren, Jen, Neaton, James D., Van 't Wout, Angã©lique B., Lubomirov, Rubin, Colombo, Sara, Martinez, Raquel, Rauch, Andri, Gã¼nthard, Huldrych F., Neuhaus, Jacqueline, Wentworth, Deborah, Van Manen, Danielle, Gras, Luuk A., Schuitemaker, Hanneke, Albini, Laura, Torti, Carlo, Jacobson, Lisa P., Li, Xiuhong, Kingsley, Lawrence A., Carli, Federica, Guaraldi, Giovanni, Ford, Emily S., Sereti, Irini, Hadigan, Colleen, Martinez, Esteban, Arnedo, Mireia, Egaã±a gorroã±o, Lander, Gatell, Jose M., Law, Matthew, Bendall, Courtney, Petoumenos, Kathy, Rockstroh, Jã¼rgen, Wasmuth, Jan christian, Kabamba, Kabeya, Delforge, Marc, De Wit, Stephane, Berger, Florian, Mauss, Stefan, De Paz Sierra, Mariana, Losso, Marcelo, Belloso, Waldo H., Leyes, Maria, Campins, Antoni, Mondi, Annalisa, De Luca, Andrea, Bernardino, Ignacio, Barriuso iglesias, Mã³nica, Torrecilla rodriguez, Ana, Gonzalez garcia, Juan, Arribas, Josã© R., Fanti, Iuri, Gel, Silvia, Puig, Jordi, Negredo, Eugenia, Gutierrez, Mar, Domingo, Pere, Fischer, Julia, Fã¤tkenheuer, Gerd, Alonso villaverde, Carlo, Macken, Alan, Woo, Jame, Mcginty, Tara, Mallon, Patrick, Mangili, Alexandra, Skinner, Sally, Wanke, Christine A., Reiss, Peter, Weber, Rainer, Bucher, Heiner C., Fellay, Jacque, Telenti, Amalio, Tarr, Philip E. Swiss Hiv Cohort, and Castagna, Antonella
- Subjects
Male ,HIV Infections ,Genome-wide association study ,030204 cardiovascular system & hematology ,2726 Microbiology (medical) ,10234 Clinic for Infectious Diseases ,Coronary artery disease ,0302 clinical medicine ,ddc:590 ,Risk Factors ,Abacavir ,80 and over ,genetics ,030212 general & internal medicine ,Family history ,Articles and Commentaries ,Aged, 80 and over ,education.field_of_study ,medicine.diagnostic_test ,traditional risk factor ,Single Nucleotide ,Middle Aged ,3. Good health ,Infectious Diseases ,traditional risk factors ,Cohort ,Female ,HIV infection ,antiretroviral therapy ,coronary artery disease ,Human ,medicine.drug ,Adult ,Microbiology (medical) ,medicine.medical_specialty ,Adolescent ,Population ,Infectious Disease ,610 Medicine & health ,Polymorphism, Single Nucleotide ,Genetic Predisposition to Disease ,Aged ,Coronary Artery Disease ,Humans ,Polymorphism ,Young Adult ,03 medical and health sciences ,Internal medicine ,medicine ,education ,Genetic testing ,business.industry ,Risk Factor ,2725 Infectious Diseases ,Odds ratio ,medicine.disease ,Immunology ,genetic ,business - Abstract
BACKGROUND: Persons infected with human immunodeficiency virus (HIV) have increased rates of coronary artery disease (CAD). The relative contribution of genetic background, HIV-related factors, antiretroviral medications, and traditional risk factors to CAD has not been fully evaluated in the setting of HIV infection.METHODS: In the general population, 23 common single-nucleotide polymorphisms (SNPs) were shown to be associated with CAD through genome-wide association analysis. Using the Metabochip, we genotyped 1875 HIV-positive, white individuals enrolled in 24 HIV observational studies, including 571 participants with a first CAD event during the 9-year study period and 1304 controls matched on sex and cohort.RESULTS: A genetic risk score built from 23 CAD-associated SNPs contributed significantly to CAD (P = 2.9 × 10(-4)). In the final multivariable model, participants with an unfavorable genetic background (top genetic score quartile) had a CAD odds ratio (OR) of 1.47 (95% confidence interval [CI], 1.05-2.04). This effect was similar to hypertension (OR = 1.36; 95% CI, 1.06-1.73), hypercholesterolemia (OR = 1.51; 95% CI, 1.16-1.96), diabetes (OR = 1.66; 95% CI, 1.10-2.49), ≥ 1 year lopinavir exposure (OR = 1.36; 95% CI, 1.06-1.73), and current abacavir treatment (OR = 1.56; 95% CI, 1.17-2.07). The effect of the genetic risk score was additive to the effect of nongenetic CAD risk factors, and did not change after adjustment for family history of CAD.CONCLUSIONS: In the setting of HIV infection, the effect of an unfavorable genetic background was similar to traditional CAD risk factors and certain adverse antiretroviral exposures. Genetic testing may provide prognostic information complementary to family history of CAD.
- Published
- 2013
13. Release of P-TEFb from the Super Elongation Complex promotes HIV-1 latency reversal.
- Author
-
Cisneros WJ, Soliman SHA, Walter M, Simons LM, Cornish D, De Fabritiis S, Halle AW, Kim EY, Wolinsky SM, Lorenzo-Redondo R, Shilatifard A, and Hultquist JF
- Subjects
- Humans, Virus Activation drug effects, Virus Replication, Gene Expression Regulation, Viral, HIV-1 physiology, HIV-1 genetics, Virus Latency physiology, Virus Latency drug effects, Positive Transcriptional Elongation Factor B metabolism, HIV Infections virology, HIV Infections metabolism, HIV Infections drug therapy, CD4-Positive T-Lymphocytes virology, CD4-Positive T-Lymphocytes metabolism
- Abstract
The persistence of HIV-1 in long-lived latent reservoirs during suppressive antiretroviral therapy (ART) remains one of the principal barriers to a functional cure. Blocks to transcriptional elongation play a central role in maintaining the latent state, and several latency reversal strategies focus on the release of positive transcription elongation factor b (P-TEFb) from sequestration by negative regulatory complexes, such as the 7SK complex and BRD4. Another major cellular reservoir of P-TEFb is in Super Elongation Complexes (SECs), which play broad regulatory roles in host gene expression. Still, it is unknown if the release of P-TEFb from SECs is a viable latency reversal strategy. Here, we demonstrate that the SEC is not required for HIV-1 replication in primary CD4+ T cells and that a small molecular inhibitor of the P-TEFb/SEC interaction (termed KL-2) increases viral transcription. KL-2 acts synergistically with other latency reversing agents (LRAs) to reactivate viral transcription in several cell line models of latency in a manner that is, at least in part, dependent on the viral Tat protein. Finally, we demonstrate that KL-2 enhances viral reactivation in peripheral blood mononuclear cells (PBMCs) from people living with HIV (PLWH) on suppressive ART, most notably in combination with inhibitor of apoptosis protein antagonists (IAPi). Taken together, these results suggest that the release of P-TEFb from cellular SECs may be a novel route for HIV-1 latency reactivation., Competing Interests: J.F.H. has received research support, paid to Northwestern University, from Gilead Sciences, and is a paid consultant for Merck. All other authors declare no competing interests., (Copyright: © 2024 Cisneros et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2024
- Full Text
- View/download PDF
14. Effects of highly active antiretroviral therapy initiation on epigenomic DNA methylation in persons living with HIV.
- Author
-
Zhang J, Sehl ME, Shih R, Breen EC, Li F, Lu AT, Bream JH, Duggal P, Martinson J, Wolinsky SM, Martinez-Maza O, Ramirez CM, Horvath S, and Jamieson BD
- Abstract
Introduction: Highly active antiretroviral therapy (HAART) helps improve some measures of accelerated epigenetic aging in persons living with HIV (PLWH), but its overall impact on the epigenome is not fully understood. Methods: In this study, we analyzed the DNA methylation profiles of PLWH ( n = 187) shortly before and approximately 2-3 years after they started HAART, as well as matched seronegative (SN) controls ( n = 187), taken at two time intervals. Our aim was to identify specific CpGs and biologic pathways associated with HIV infection and initiation of HAART. Additionally, we attempted to identify epigenetic changes associated with HAART initiation that were independent of HIV-associated changes, using matched HIV seronegative (SN) controls (matched on age, hepatitis C status, and interval between visits) to identify CpGs that did not differ between PLWH and SN pre-HAART but were significantly associated with HAART initiation while being unrelated to HIV viral load. Epigenome-wide association studies (EWAS) on >850,000 CpG sites were performed using pre- and post-HAART samples from PLWH. The results were then annotated using the Genomic Regions Enrichment of Annotations Tool (GREAT). Results: When only pre- and post-HAART visits in PLWH were compared, gene ontologies related to immune function and diseases related to immune function were significant, though with less significance for PLWH with detectable HIV viral loads (>50 copies/mL) at the post-HAART visit. To specifically elucidate the effects of HAART separately from HIV-induced methylation changes, we performed EWAS of HAART while also controlling for HIV viral load, and found gene ontologies associated with transplant rejection, transplant-related diseases, and other immunologic signatures. Additionally, we performed a more focused analysis that examined CpGs reaching genome-wide significance ( p < 1 × 10
-7 ) from the viral load-controlled EWAS that did not differ between all PLWH and matched SN controls pre-HAART. These CpGs were found to be near genes that play a role in retroviral drug metabolism, diffuse large B cell lymphoma proliferation, and gastric cancer metastasis. Discussion: Overall, this study provides insight into potential biological functions associated with DNA methylation changes induced by HAART initiation in persons living with HIV., Competing Interests: SH is a founder of the non-profit Epigenetic Clock Development Foundation which plans to license several patents from his employer UC Regents. These patents list SH as inventor. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. CR declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision., (Copyright © 2024 Zhang, Sehl, Shih, Breen, Li, Lu, Bream, Duggal, Martinson, Wolinsky, Martinez-Maza, Ramirez, Horvath and Jamieson.)- Published
- 2024
- Full Text
- View/download PDF
15. Decreased but persistent epigenetic age acceleration is associated with changes in T-cell subsets after initiation of highly active antiretroviral therapy in persons living with HIV.
- Author
-
Sehl ME, Breen EC, Shih R, Li F, Zhang J, Langfelder P, Horvath S, Bream JH, Duggal P, Martinson J, Wolinsky SM, Martinez-Maza O, Ramirez CM, and Jamieson BD
- Abstract
Introduction: Persons living with HIV (PLWH) experience the early onset of age-related illnesses, even in the setting of successful human immunodeficiency virus (HIV) suppression with highly active antiretroviral therapy (HAART). HIV infection is associated with accelerated epigenetic aging as measured using DNA methylation (DNAm)-based estimates of biological age and of telomere length (TL)., Methods: DNAm levels (Infinium MethylationEPIC BeadChip) from peripheral blood mononuclear cells from 200 PLWH and 199 HIV-seronegative (SN) participants matched on chronologic age, hepatitis C virus, and time intervals were used to calculate epigenetic age acceleration, expressed as age-adjusted acceleration residuals from 4 epigenetic clocks [Horvath's pan-tissue age acceleration residual (AAR), extrinsic epigenetic age acceleration (EEAA), phenotypic epigenetic age acceleration (PEAA), and grim epigenetic age acceleration (GEAA)] plus age-adjusted DNAm-based TL (aaDNAmTL). Epigenetic age acceleration was compared for PLWH and SN participants at two visits: up to 1.5 years prior and 2-3 years after HAART (or equivalent visits). Flow cytometry was performed in PLWH and SN participants at both visits to evaluate T-cell subsets., Results: Epigenetic age acceleration in PLWH decreased after the initiation of HAART but remained greater post-HAART than that in age-matched SN participants, with differences in medians of 6.6, 9.1, and 7.7 years for AAR, EEAA, and PEAA, respectively, and 0.39 units of aaDNAmTL shortening (all p < 0.001). Cumulative HIV viral load after HAART initiation was associated with some epigenetic acceleration (EEAA, PEAA, and aaDNAmTL), but even PLWH with undetectable HIV post-HAART showed persistent epigenetic age acceleration compared to SN participants ( p < 0.001). AAR, EEAA, and aaDNAmTL showed significant associations with total, naïve, and senescent CD8 T-cell counts; the total CD4 T-cell counts were associated with AAR, EEAA, and PEAA ( p = 0.04 to <0.001). In an epigenome-wide analysis using weighted gene co-methylation network analyses, 11 modules demonstrated significant DNAm differences pre- to post-HAART initiation. Of these, nine were previously identified as significantly different from pre- to post-HIV infection but in the opposite direction., Discussion: In this large longitudinal study, we demonstrated that, although the magnitude of the difference decreases with HAART is associated with the cumulative viral load, PLWH are persistently epigenetically older than age-matched SN participants even after the successful initiation of HAART, and these changes are associated with changes in T-cell subsets., Competing Interests: SH is a founder of the non-profit Epigenetic Clock Development Foundation which plans to license several patents from his employer UC Regents. These patents list SH as inventor. He is also employed by Altos Labs. CR declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Sehl, Breen, Shih, Li, Zhang, Langfelder, Horvath, Bream, Duggal, Martinson, Wolinsky, Martinez-Maza, Ramirez and Jamieson.)
- Published
- 2024
- Full Text
- View/download PDF
16. Immunoglobulin G N-glycan markers of accelerated biological aging during chronic HIV infection.
- Author
-
Giron LB, Liu Q, Adeniji OS, Yin X, Kannan T, Ding J, Lu DY, Langan S, Zhang J, Azevedo JLLC, Li SH, Shalygin S, Azadi P, Hanna DB, Ofotokun I, Lazar J, Fischl MA, Haberlen S, Macatangay B, Adimora AA, Jamieson BD, Rinaldo C, Merenstein D, Roan NR, Kutsch O, Gange S, Wolinsky SM, Witt MD, Post WS, Kossenkov A, Landay AL, Frank I, Tien PC, Gross R, Brown TT, and Abdel-Mohsen M
- Subjects
- Male, Humans, Female, Immunoglobulin G, Cross-Sectional Studies, Aging, Inflammation complications, Polysaccharides, HIV Infections, Aging, Premature
- Abstract
People living with HIV (PLWH) experience increased vulnerability to premature aging and inflammation-associated comorbidities, even when HIV replication is suppressed by antiretroviral therapy (ART). However, the factors associated with this vulnerability remain uncertain. In the general population, alterations in the N-glycans on IgGs trigger inflammation and precede the onset of aging-associated diseases. Here, we investigate the IgG N-glycans in cross-sectional and longitudinal samples from 1214 women and men, living with and without HIV. PLWH exhibit an accelerated accumulation of pro-aging-associated glycan alterations and heightened expression of senescence-associated glycan-degrading enzymes compared to controls. These alterations correlate with elevated markers of inflammation and the severity of comorbidities, potentially preceding the development of such comorbidities. Mechanistically, HIV-specific antibodies glycoengineered with these alterations exhibit a reduced ability to elicit anti-HIV Fc-mediated immune activities. These findings hold potential for the development of biomarkers and tools to identify and prevent premature aging and comorbidities in PLWH., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
17. Association of urine biomarkers of kidney health with subclinical cardiovascular disease among men with and without HIV.
- Author
-
Lai M, Madden E, Shlipak MG, Scherzer R, Post WS, Vittinghoff E, Haberlen S, Brown TT, Wolinsky SM, Witt MD, Ho K, Abraham AG, Parikh CR, Budoff M, and Estrella MM
- Subjects
- Male, Humans, Female, Cohort Studies, Albuminuria, Cross-Sectional Studies, Constriction, Pathologic complications, Risk Factors, Kidney, Biomarkers, HIV Infections complications, HIV Infections epidemiology, Coronary Artery Disease epidemiology, Cardiovascular Diseases complications, Plaque, Atherosclerotic
- Abstract
Objective: The aim of this study was to determine whether urine biomarkers of kidney health are associated with subclinical cardiovascular disease among men with and without HIV., Design: A cross-sectional study within the Multicenter AIDS Cohort Study (MACS) among 504 men with and without HIV infection who underwent cardiac computed tomography scans and had urine biomarkers measured within the preceding 2 years., Methods: Our primary predictors were four urine biomarkers of endothelial (albuminuria), proximal tubule dysfunction (alpha-1-microglobulin [A1 M] and injury (kidney injury molecule-1 [KIM-1]) and tubulointerstitial fibrosis (pro-collagen-III N-terminal peptide [PIIINP]). These were evaluated for association with coronary artery calcium (CAC) prevalence, CAC extent, total plaque score, and total segment stenosis using multivariable regression., Results: Of the 504 participants, 384 were men with HIV (MWH) and 120 were men without HIV. In models adjusted for sociodemographic factors, cardiovascular disease risk factors, eGFR, and HIV-related factors, each two-fold higher concentration of albuminuria was associated with a greater extent of CAC (1.35-fold higher, 95% confidence interval 1.11-1.65), and segment stenosis (1.08-fold greater, 95% confidence interval 1.01-1.16). Associations were similar between MWH and men without HIV in stratified analyses. The third quartile of A1 M showed an association with greater CAC extent, total plaque score, and total segment stenosis, compared with the lowest quartile., Conclusion: Worse endothelial and proximal tubule dysfunction, as reflected by higher urine albumin and A1 M, were associated with greater CAC extent and coronary artery stenosis., (Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
18. Proteomic and genetic analyses of influenza A viruses identify pan-viral host targets.
- Author
-
Haas KM, McGregor MJ, Bouhaddou M, Polacco BJ, Kim EY, Nguyen TT, Newton BW, Urbanowski M, Kim H, Williams MAP, Rezelj VV, Hardy A, Fossati A, Stevenson EJ, Sukerman E, Kim T, Penugonda S, Moreno E, Braberg H, Zhou Y, Metreveli G, Harjai B, Tummino TA, Melnyk JE, Soucheray M, Batra J, Pache L, Martin-Sancho L, Carlson-Stevermer J, Jureka AS, Basler CF, Shokat KM, Shoichet BK, Shriver LP, Johnson JR, Shaw ML, Chanda SK, Roden DM, Carter TC, Kottyan LC, Chisholm RL, Pacheco JA, Smith ME, Schrodi SJ, Albrecht RA, Vignuzzi M, Zuliani-Alvarez L, Swaney DL, Eckhardt M, Wolinsky SM, White KM, Hultquist JF, Kaake RM, García-Sastre A, and Krogan NJ
- Subjects
- Humans, Influenza A Virus, H3N2 Subtype metabolism, Proteomics, Virus Replication genetics, SARS-CoV-2, Antiviral Agents metabolism, Host-Pathogen Interactions genetics, Influenza A virus genetics, Influenza, Human genetics, Influenza A Virus, H5N1 Subtype genetics, COVID-19
- Abstract
Influenza A Virus (IAV) is a recurring respiratory virus with limited availability of antiviral therapies. Understanding host proteins essential for IAV infection can identify targets for alternative host-directed therapies (HDTs). Using affinity purification-mass spectrometry and global phosphoproteomic and protein abundance analyses using three IAV strains (pH1N1, H3N2, H5N1) in three human cell types (A549, NHBE, THP-1), we map 332 IAV-human protein-protein interactions and identify 13 IAV-modulated kinases. Whole exome sequencing of patients who experienced severe influenza reveals several genes, including scaffold protein AHNAK, with predicted loss-of-function variants that are also identified in our proteomic analyses. Of our identified host factors, 54 significantly alter IAV infection upon siRNA knockdown, and two factors, AHNAK and coatomer subunit COPB1, are also essential for productive infection by SARS-CoV-2. Finally, 16 compounds targeting our identified host factors suppress IAV replication, with two targeting CDK2 and FLT3 showing pan-antiviral activity across influenza and coronavirus families. This study provides a comprehensive network model of IAV infection in human cells, identifying functional host targets for pan-viral HDT., (© 2023. Springer Nature Limited.)
- Published
- 2023
- Full Text
- View/download PDF
19. Author Correction: Africa-specific human genetic variation near CHD1L associates with HIV-1 load.
- Author
-
McLaren PJ, Porreca I, Iaconis G, Mok HP, Mukhopadhyay S, Karakoc E, Cristinelli S, Pomilla C, Bartha I, Thorball CW, Tough RH, Angelino P, Kiar CS, Carstensen T, Fatumo S, Porter T, Jarvis I, Skarnes WC, Bassett A, DeGorter MK, Sathya Moorthy MP, Tuff JF, Kim EY, Walter M, Simons LM, Bashirova A, Buchbinder S, Carrington M, Cossarizza A, De Luca A, Goedert JJ, Goldstein DB, Haas DW, Herbeck JT, Johnson EO, Kaleebu P, Kilembe W, Kirk GD, Kootstra NA, Kral AH, Lambotte O, Luo M, Mallal S, Martinez-Picado J, Meyer L, Miro JM, Moodley P, Motala AA, Mullins JI, Nam K, Obel N, Pirie F, Plummer FA, Poli G, Price MA, Rauch A, Theodorou I, Trkola A, Walker BD, Winkler CA, Zagury JF, Montgomery SB, Ciuffi A, Hultquist JF, Wolinsky SM, Dougan G, Lever AML, Gurdasani D, Groom H, Sandhu MS, and Fellay J
- Published
- 2023
- Full Text
- View/download PDF
20. Africa-specific human genetic variation near CHD1L associates with HIV-1 load.
- Author
-
McLaren PJ, Porreca I, Iaconis G, Mok HP, Mukhopadhyay S, Karakoc E, Cristinelli S, Pomilla C, Bartha I, Thorball CW, Tough RH, Angelino P, Kiar CS, Carstensen T, Fatumo S, Porter T, Jarvis I, Skarnes WC, Bassett A, DeGorter MK, Sathya Moorthy MP, Tuff JF, Kim EY, Walter M, Simons LM, Bashirova A, Buchbinder S, Carrington M, Cossarizza A, De Luca A, Goedert JJ, Goldstein DB, Haas DW, Herbeck JT, Johnson EO, Kaleebu P, Kilembe W, Kirk GD, Kootstra NA, Kral AH, Lambotte O, Luo M, Mallal S, Martinez-Picado J, Meyer L, Miro JM, Moodley P, Motala AA, Mullins JI, Nam K, Obel N, Pirie F, Plummer FA, Poli G, Price MA, Rauch A, Theodorou I, Trkola A, Walker BD, Winkler CA, Zagury JF, Montgomery SB, Ciuffi A, Hultquist JF, Wolinsky SM, Dougan G, Lever AML, Gurdasani D, Groom H, Sandhu MS, and Fellay J
- Subjects
- Humans, Cell Line, Africa, Chromosomes, Human, Pair 1 genetics, Alleles, RNA, Long Noncoding genetics, Virus Replication, DNA Helicases genetics, DNA Helicases metabolism, DNA-Binding Proteins genetics, DNA-Binding Proteins metabolism, Genetic Variation, HIV Infections genetics, HIV-1 growth & development, HIV-1 physiology, Viral Load genetics
- Abstract
HIV-1 remains a global health crisis
1 , highlighting the need to identify new targets for therapies. Here, given the disproportionate HIV-1 burden and marked human genome diversity in Africa2 , we assessed the genetic determinants of control of set-point viral load in 3,879 people of African ancestries living with HIV-1 participating in the international collaboration for the genomics of HIV3 . We identify a previously undescribed association signal on chromosome 1 where the peak variant associates with an approximately 0.3 log10 -transformed copies per ml lower set-point viral load per minor allele copy and is specific to populations of African descent. The top associated variant is intergenic and lies between a long intergenic non-coding RNA (LINC00624) and the coding gene CHD1L, which encodes a helicase that is involved in DNA repair4 . Infection assays in iPS cell-derived macrophages and other immortalized cell lines showed increased HIV-1 replication in CHD1L-knockdown and CHD1L-knockout cells. We provide evidence from population genetic studies that Africa-specific genetic variation near CHD1L associates with HIV replication in vivo. Although experimental studies suggest that CHD1L is able to limit HIV infection in some cell types in vitro, further investigation is required to understand the mechanisms underlying our observations, including any potential indirect effects of CHD1L on HIV spread in vivo that our cell-based assays cannot recapitulate., (© 2023. The Author(s), under exclusive licence to Springer Nature Limited.)- Published
- 2023
- Full Text
- View/download PDF
21. Erratum: Accelerated aging with HIV begins at the time of initial HIV infection.
- Author
-
Breen EC, Sehl ME, Shih R, Langfelder P, Wang R, Horvath S, Bream JH, Duggal P, Martinson J, Wolinsky SM, Martínez-Maza O, Ramirez CM, and Jamieson BD
- Abstract
[This corrects the article DOI: 10.1016/j.isci.2022.104488.]., (© 2023 The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
22. Mosaic chromosomal alterations detected in men living with HIV and the relationship to non-Hodgkin lymphoma.
- Author
-
Lin SH, Khan SM, Zhou W, Brown DW, Vergara C, Wolinsky SM, Martínez-Maza O, Margolick JB, Martinson JJ, Hussain SK, Engels EA, and Machiela MJ
- Subjects
- Humans, Male, Cohort Studies, Chromosomes, Human, Y, Mosaicism, HIV Infections complications, Lymphoma, Non-Hodgkin epidemiology, Lymphoma, Non-Hodgkin genetics
- Abstract
Objectives: People with HIV (PWH) have an elevated risk of non-Hodgkin lymphoma (NHL) and other diseases. Studying clonal hematopoiesis (CH), the clonal expansion of mutated hematopoietic stem cells, could provide insights regarding elevated NHL risk., Design: Cohort analysis of participants in the Multicenter AIDS Cohort Study ( N = 5979)., Methods: Mosaic chromosomal alterations (mCAs), a type of CH, were detected from genotyping array data using MoChA. We compared CH prevalence in men with HIV (MWH) to HIV-uninfected men using logistic regression, and among MWH, assessed the associations of CH with NHL incidence and overall mortality using Poisson regression., Results: Comparing MWH to HIV-uninfected men, we observed no difference in the frequency of autosomal mCAs (3.9% vs. 3.6%, P -value = 0.09) or mosaic loss of the Y chromosome (mLOY) (1.4% vs. 2.9%, P -value = 0.13). Autosomal mCAs involving copy-neutral loss of heterozygosity (CN-LOH) of chromosome 14q were more common in MWH. Among MWH, mCAs were not associated with subsequent NHL incidence (autosomal mCA P -value = 0.65, mLOY P -value = 0.48). However, two MWH with diffuse large B-cell lymphoma had overlapping CN-LOH mCAs on chromosome 19 spanning U2AF2 (involved in RNA splicing), and one MWH with Burkitt lymphoma had high-frequency mCAs involving chromosome 1 gain and chromosome 17 CN-LOH (cell fractions 22.1% and 25.0%, respectively). mCAs were not associated with mortality among MWH (autosomal mCA P -value = 0.52, mLOY P -value = 0.93)., Conclusions: We found limited evidence for a relationship between HIV infection and mCAs. Although mCAs were not significantly associated with NHL, mCAs detected in several NHL cases indicate a need for further investigation., (Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
23. Enhancing HIV-1 latency reversal through regulating the elongating RNA Pol II pause-release by a small-molecule disruptor of PAF1C.
- Author
-
Soliman SHA, Cisneros WJ, Iwanaszko M, Aoi Y, Ganesan S, Walter M, Zeidner JM, Mishra RK, Kim EY, Wolinsky SM, Hultquist JF, and Shilatifard A
- Subjects
- Humans, Molecular Docking Simulation, Cell Line, Transcription, Genetic, Transcription Factors genetics, RNA Polymerase II metabolism, HIV-1 genetics, HIV-1 metabolism
- Abstract
The polymerase-associated factor 1 complex (PAF1C) is a key, post-initiation transcriptional regulator of both promoter-proximal pausing and productive elongation catalyzed by RNA Pol II and is also involved in transcriptional repression of viral gene expression during human immunodeficiency virus-1 (HIV-1) latency. Using a molecular docking-based compound screen in silico and global sequencing-based candidate evaluation in vivo, we identified a first-in-class, small-molecule inhibitor of PAF1C (iPAF1C) that disrupts PAF1 chromatin occupancy and induces global release of promoter-proximal paused RNA Pol II into gene bodies. Transcriptomic analysis revealed that iPAF1C treatment mimics acute PAF1 subunit depletion and impairs RNA Pol II pausing at heat shock-down-regulated genes. Furthermore, iPAF1C enhances the activity of diverse HIV-1 latency reversal agents both in cell line latency models and in primary cells from persons living with HIV-1. In sum, this study demonstrates that efficient disruption of PAF1C by a first-in-class, small-molecule inhibitor may have therapeutic potential for improving current HIV-1 latency reversal strategies.
- Published
- 2023
- Full Text
- View/download PDF
24. Gut Microbiota, Plasma Metabolomic Profiles, and Carotid Artery Atherosclerosis in HIV Infection.
- Author
-
Wang Z, Peters BA, Usyk M, Xing J, Hanna DB, Wang T, Post WS, Landay AL, Hodis HN, Weber K, French A, Golub ET, Lazar J, Gustafson D, Kassaye S, Aouizerat B, Haberlen S, Malvestutto C, Budoff M, Wolinsky SM, Sharma A, Anastos K, Clish CB, Kaplan RC, Burk RD, and Qi Q
- Subjects
- Carotid Arteries pathology, Cross-Sectional Studies, Female, Humans, Lysophosphatidylcholines, Male, Atherosclerosis pathology, Carotid Artery Diseases pathology, Carotid Stenosis pathology, Gastrointestinal Microbiome, HIV Infections complications, HIV Infections diagnosis, Plaque, Atherosclerotic pathology
- Abstract
Background: Alterations in gut microbiota and blood metabolomic profiles have been implicated in HIV infection and cardiovascular disease. However, it remains unclear whether alterations in gut microbiota may contribute to disrupted host blood metabolomic profiles in relation to atherosclerosis, especially in the context of HIV infection., Methods: We analyzed cross-sectional associations between gut microbiota features and carotid artery plaque in 361 women with or at high risk of HIV (67% HIV+), and further integrated plaque-associated microbial features with plasma lipidomic/metabolomic profiles. Furthermore, in 737 women and men, we examined prospective associations of baseline gut bacteria-associated lipidomic and metabolomic profiles with incident carotid artery plaque over 7-year follow-up., Results: We found 2 potentially pathogenic bacteria, Fusobacterium and Proteus , were associated with carotid artery plaque; while the beneficial butyrate producer Odoribacter was inversely associated with plaque. Fusobacterium and Proteus were associated with multiple lipids/metabolites which were clustered into 8 modules in network. A module comprised of 9 lysophosphatidylcholines and lysophosphatidylethanolamines and a module comprised of 9 diglycerides were associated with increased risk of carotid artery plaque (risk ratio [95% CI], 1.34 [1.09-1.64] and 1.24 [1.02-1.51] per SD increment, respectively). Functional analyses identified bacterial enzymes in lipid metabolism associated with these plasma lipids. In particular, phospholipase A1 and A2 are the key enzymes in the reactions producing lysophosphatidylcholines and lysophosphatidylethanolamines., Conclusions: Among individuals with or at high risk of HIV infection, we identified altered gut microbiota and related functional capacities in the lipid metabolism associated with disrupted plasma lipidomic profiles and carotid artery atherosclerosis.
- Published
- 2022
- Full Text
- View/download PDF
25. Accelerated aging with HIV begins at the time of initial HIV infection.
- Author
-
Breen EC, Sehl ME, Shih R, Langfelder P, Wang R, Horvath S, Bream JH, Duggal P, Martinson J, Wolinsky SM, Martínez-Maza O, Ramirez CM, and Jamieson BD
- Abstract
Living with HIV infection is associated with early onset of aging-related chronic conditions, sometimes described as accelerated aging. Epigenetic DNA methylation patterns can evaluate acceleration of biological age relative to chronological age. The impact of initial HIV infection on five epigenetic measures of aging was examined before and approximately 3 years after HIV infection in the same individuals (n=102). Significant epigenetic age acceleration (median 1.9-4.8 years) and estimated telomere length shortening (all p ≤ 0.001) were observed from pre-to post-HIV infection, and remained significant in three epigenetic measures after controlling for T cell changes. No acceleration was seen in age- and time interval-matched HIV-uninfected controls. Changes in genome-wide co-methylation clusters were also significantly associated with initial HIV infection (p≤ 2.0 × 10
-4 ). These longitudinal observations clearly demonstrate an early and substantial impact of HIV infection on the epigenetic aging process, and suggest a role for HIV itself in the earlier onset of clinical aging., Competing Interests: Peter Langfelder is a paid consultant for The Bioinformatics CRO, Inc and Quantigic Genomics, LLC. Steve Horvath is a founder of the non-profit Epigenetic Clock Development Foundation which plans to license several patents from his employer UC Regents. These patents list SH as inventor., (© 2022 The Author(s).)- Published
- 2022
- Full Text
- View/download PDF
26. Increased Rate of Epigenetic Aging in Men Living With HIV Prior to Treatment.
- Author
-
Sehl ME, Breen EC, Shih R, Chen L, Wang R, Horvath S, Bream JH, Duggal P, Martinson J, Wolinsky SM, Martinez-Maza O, Ramirez CM, and Jamieson BD
- Abstract
Background: Epigenetic aging is accelerated in tissues of persons living with HIV (PLWH) and may underlie the early onset of age-related illnesses. This study examines the rate-of-change in epigenetic age in PLWH following HIV infection but before HAART, using archived longitudinal samples from the Multicenter AIDS Cohort Study. Methods: DNA was isolated from cryopreserved peripheral blood mononuclear cells from 101 men living with HIV, with baseline visit <2.5 years after HIV seroconversion (Visit 1) and follow-up visit <1.5 years before the initiation of HAART (Visit 2), and 100 HIV-uninfected men matched on age and visits with comparable time intervals. DNA methylation (DNAm) age was estimated for five clocks (Pan-tissue, Extrinsic, Phenotypic, Grim, and Skin & Blood age), and a DNAm-based estimate of telomere length (DNAmTL). Multivariate linear regression models were used to examine baseline factors associated with rate-of-aging, defined as (DNAm age visit 2-DNAm age visit 1)/(age visit 2-age visit 1). Results: Epigenetic age increased approximately twice as fast in PLWH as uninfected controls (Pan-tissue, Extrinsic, and Phenotypic clocks). Shortening of DNAmTL was nearly 3-fold faster in PLWH than controls. Faster rate-of-aging was associated with HIV status (Pan-Tissue, Extrinsic, Phenotypic, and DNAmTL), white race (Extrinsic, DNAmTL), higher cumulative HIV viral load (Grim), and lower baseline DNAm age (Phenotypic, Skin & Blood). Conclusion: Epigenetic rates-of-aging were significantly faster for untreated PLWH. Our findings expand on the important impact of HIV infection on biologic aging, both in elevating epigenetic age and increasing the rate-of-aging in the years following infection., Competing Interests: SH is listed as inventor of several patent applications surrounding epigenetic biomarkers of aging. The remaining authors declare no competing interests., (Copyright © 2022 Sehl, Breen, Shih, Chen, Wang, Horvath, Bream, Duggal, Martinson, Wolinsky, Martinez-Maza, Ramirez and Jamieson.)
- Published
- 2022
- Full Text
- View/download PDF
27. Transcriptome-wide changes in gene expression, splicing, and lncRNAs in response to a live attenuated dengue virus vaccine.
- Author
-
Kim EY, Che Y, Dean HJ, Lorenzo-Redondo R, Stewart M, Keller CK, Whorf D, Mills D, Dulin NN, Kim T, Votoupal M, Walter M, Fernandez-Sesma A, Kim H, and Wolinsky SM
- Subjects
- Antibodies, Neutralizing immunology, Dengue virology, Dengue Virus genetics, Humans, Immunogenicity, Vaccine immunology, Vaccines, Attenuated administration & dosage, Vaccines, Attenuated immunology, Viral Vaccines immunology, Viral Vaccines pharmacology, Antibodies, Viral immunology, Dengue Vaccines immunology, Dengue Virus pathogenicity, RNA, Long Noncoding genetics, Transcriptome genetics
- Abstract
The tetravalent dengue vaccine candidate, TAK-003, induces a functional antibody response, but the titers of antibodies against the four serotypes of the dengue virus (DENV) can vary. Here, through a transcriptomic analysis on whole blood collected from recipients of a two-dose schedule of TAK-003, we examine gene expression, splicing, and transcript isoform-level changes for both protein-coding and noncoding genes to broaden our understanding of the immune response. Our analysis reveals a dynamic pattern of vaccine-associated regulation of long noncoding RNAs (lncRNAs), differential splicing of interferon-stimulated gene exons, and gene expression changes related to multiple signaling pathways that detect viral infection. Co-expression networks isolate immune cell-type-related and interferon-response modules that represent specific biological processes that correlate with more robust antibody responses. These data provide insights into the early determinants of the variable immune response to the vaccine, highlighting the significance of splicing and isoform-level gene regulatory mechanisms in defining vaccine immunogenicity., Competing Interests: Declaration of interests H.J.D. was an employee (retired) of Takeda Pharmaceutical Company Ltd. The content is solely the responsibility of the authors. It does not necessarily represent the views of Takeda Pharmaceutical Company Ltd or NIH. The other authors declare no competing interests., (Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
28. Outcomes of acute hepatitis B virus (HBV) in HIV infection with and without HBV-active antiretroviral therapy.
- Author
-
Falade-Nwulia O, Seaberg EC, Snider AE, Rinaldo CR, Wolinsky SM, Witt MD, and Thio CL
- Subjects
- Antiretroviral Therapy, Highly Active, Cohort Studies, Hepatitis B virus, Humans, Male, HIV Infections complications, HIV Infections drug therapy, Hepatitis B complications, Hepatitis B, Chronic complications, Hepatitis B, Chronic drug therapy
- Abstract
Men with acute hepatitis B virus (HBV) infection in the Multicenter AIDS Cohort Study from 1985 to 2013 had serological testing to determine proportions with HBV recovery or chronic hepatitis B (CHB). A similar proportion of men without human immunodeficiency virus (HIV) and men with HIV receiving HBV-active antiretroviral therapy (ART) developed CHB [8.2%, 95% confidence interval (CI) 3.8-15.0% vs. 7.7%, 95% CI 2.00-36.0%]. In contrast, 17.5% (95% CI 8.7-29.9%) of men living with HIV, not on HBV-active ART developed CHB. HBV-active ART protects against developing CHB., (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
29. Acrolein and other toxicant exposures in relation to cardiovascular disease among marijuana and tobacco smokers in a longitudinal cohort of HIV-positive and negative adults.
- Author
-
Lorenz DR, Misra V, Chettimada S, Uno H, Wang L, Blount BC, De Jesús VR, Gelman BB, Morgello S, Wolinsky SM, and Gabuzda D
- Abstract
Background: Marijuana smoke contains some of the same toxicants present in tobacco smoke. Marijuana smoking is prevalent among HIV+ individuals, but few studies have characterized smoke-related toxicants or associated health outcomes in exclusive marijuana users., Methods: This longitudinal study included 245 participants over age 40 (76% HIV+). 33 plasma and 28 urine metabolites of nicotine, ∆-9-trans-tetrahydrocannabinol, polycyclic aromatic hydrocarbons, and volatile organic compounds were assayed by liquid or gas chromatography/mass spectrometry. Exposures and health outcomes were assessed from surveys and medical records., Findings: At baseline, 18% of participants were marijuana-only smokers, 20% tobacco-only smokers, and 24% dual marijuana-tobacco smokers (median (IQR) age 53 (47-60) years, 78% male, 54% white race). Marijuana smoking was independently associated with elevated plasma naphthalenes, 2-hydroxyfluorene sulfate, 4-vinylphenol sulfate, and o-cresol sulfate (p< 0·05) and urine acrylonitrile and acrylamide metabolites ( p< 0·05), but levels were lower than those associated with tobacco smoking. Acrolein metabolite N-Acetyl-S-(3-hydroxypropyl)-l-cysteine (3HPMA) was significantly elevated in plasma and urine in tobacco-only and dual but not marijuana-only smokers, and correlated with nicotine metabolites ( p< 0·05). The highest tertile of 3HPMA was associated with increased cardiovascular disease diagnoses independent of tobacco smoking, traditional risk factors, and HIV status (odds ratio [95% CI] 3·34 [1·31-8·57]; p = 0·012)., Interpretation: Smoke-related toxicants, including acrylonitrile and acrylamide metabolites, are detectable in exclusive marijuana smokers, but exposures are lower compared with tobacco or dual smokers. Acrolein exposure is increased by tobacco smoking but not exclusive marijuana smoking in HIV+ and HIV- adults, and contributes to cardiovascular disease in tobacco smokers., Funding: U.S. NIH., Competing Interests: DL, VM, SC, HU, BG, SM, SW and DG report grants from the NIH during the conduct of the study. All other authors have nothing to disclose., (© 2020 The Authors.)
- Published
- 2021
- Full Text
- View/download PDF
30. Small RNA sequencing of extracellular vesicles identifies circulating miRNAs related to inflammation and oxidative stress in HIV patients.
- Author
-
Chettimada S, Lorenz DR, Misra V, Wolinsky SM, and Gabuzda D
- Subjects
- Adult, Female, HIV Infections genetics, High-Throughput Nucleotide Sequencing, Humans, Male, Middle Aged, Oxidative Stress genetics, CD4-Positive T-Lymphocytes immunology, Circulating MicroRNA genetics, Extracellular Vesicles genetics, Genetic Markers genetics, HIV Infections immunology, HIV-1 physiology, Inflammation genetics
- Abstract
Background: Extracellular vesicles (EVs) are nano-sized particles secreted by most cells. EVs carry nucleic acids that hold promise as potential biomarkers in various diseases. Human immunodeficiency virus type 1 (HIV) infects CD4+ T cells and induces immune dysfunction, inflammation, and EV secretion, but little is known about EV small RNA cargo in relation to immune dysregulation in HIV-infected individuals. Here, we characterize small RNA carried by circulating EVs in HIV-positive subjects on antiretroviral therapy (ART) relative to uninfected controls by next-generation RNA sequencing., Results: Plasma EVs isolated from HIV-positive and HIV-negative subjects in test (n = 24) and validation (n = 16) cohorts were characterized by electron microscopy, nanoparticle tracking analysis, and immunoblotting for exosome markers. EVs were more abundant in plasma from HIV-positive compared to HIV-negative subjects. Small RNA sequencing of plasma EVs in the test cohort identified diverse small RNA species including miRNA, piRNA, snRNA, snoRNA, tRNA, and rRNA, with miRNA being the most abundant. A total of 351 different miRNAs were detected in plasma EVs, with the top 50 miRNAs accounting for 90% of all miRNA reads. miR-26a-5p was the most abundant miRNA, followed by miR-21-5p and miR-148-3p. qRT-PCR analysis showed that six miRNAs (miR-10a-5p, - 21-5p, -27b-3p, - 122-5p, -146a-5p, - 423-5p) were significantly increased in plasma EVs from HIV-positive compared to HIV-negative subjects in the validation cohort. Furthermore, miR-21-5p, -27b-3p, -146a-5p, and - 423-5p correlated positively with metabolite markers of oxidative stress and negatively with anti-inflammatory polyunsaturated fatty acids. Over-representation and pathway enrichment analyses of miRNAs and their target genes predicted functional association with oxidative stress responses, interferon gamma signaling, Toll-like receptor signaling, TGF beta signaling, and Notch signaling., Conclusions: HIV-positive individuals on ART have increased abundance of circulating EVs carrying diverse small RNAs, with miRNAs being the most abundant. Several miRNAs associated with inflammation and oxidative stress are increased in circulating EVs of HIV-positive individuals, representing potential biomarkers of targetable pathways that contribute to disease pathogenesis.
- Published
- 2020
- Full Text
- View/download PDF
31. Comprehensive Immunoprofiling of Pediatric Zika Reveals Key Role for Monocytes in the Acute Phase and No Effect of Prior Dengue Virus Infection.
- Author
-
Michlmayr D, Kim EY, Rahman AH, Raghunathan R, Kim-Schulze S, Che Y, Kalayci S, Gümüş ZH, Kuan G, Balmaseda A, Kasarskis A, Wolinsky SM, Suaréz-Fariñas M, and Harris E
- Subjects
- Acute Disease, Child, Female, Humans, Male, Dengue Virus pathogenicity, Immunity, Innate immunology, Monocytes virology, Zika Virus pathogenicity
- Abstract
Zika virus (ZIKV) is an emerging, mosquito-borne flavivirus responsible for recent epidemics across the Americas, and it is closely related to dengue virus (DENV). Here, we study samples from 46 DENV-naive and 43 DENV-immune patients with RT-PCR-confirmed ZIKV infection at early-acute, late-acute, and convalescent time points from our pediatric cohort study in Nicaragua. We analyze the samples via RNA sequencing (RNA-seq), CyTOF, and multiplex cytokine/chemokine Luminex to generate a comprehensive, innate immune profile during ZIKV infection. Immunophenotyping and analysis of cytokines/chemokines reveal that CD14
+ monocytes play a key role during ZIKV infection. Further, we identify CD169 (Siglec-1) on CD14+ monocytes as a potential biomarker of acute ZIKV infection. Strikingly distinct transcriptomic and immunophenotypic signatures are observed at all three time points. Interestingly, pre-existing dengue immunity has minimal impact on the innate immune response to Zika. Finally, this comprehensive immune profiling and network analysis of ZIKV infection in children serves as a valuable resource., Competing Interests: Declaration of Interest The authors declare no competing interests., (Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.)- Published
- 2020
- Full Text
- View/download PDF
32. Inflammation and Risk of Depression in HIV: Prospective Findings From the Multicenter AIDS Cohort Study.
- Author
-
Lu H, Surkan PJ, Irwin MR, Treisman GJ, Breen EC, Sacktor N, Stall R, Wolinsky SM, Jacobson LP, and Abraham AG
- Subjects
- Depression epidemiology, HIV Infections psychology, Humans, Male, Prevalence, Prospective Studies, United States epidemiology, Depression etiology, HIV Infections complications, Inflammation complications, Sexual and Gender Minorities psychology
- Abstract
Studies suggest that inflammation might be involved in the pathogenesis of depression. Individuals with human immunodeficiency virus (HIV) have a higher risk of depression and elevated inflammatory profiles. Despite this, research on the link between inflammation and depression among this high-risk population is limited. We examined a sample of men who have sex with men from the Multicenter AIDS Cohort Study in prospective analyses of the association between inflammation and clinically relevant depression symptoms, defined as scores >20 on Center for Epidemiological Studies Depression Scale. We included 1,727 participants who contributed 9,287 person-visits from 1984 to 2010 (8,218 with HIV (HIV+) and 1,069 without (HIV-)). Exploratory factor analysis (EFA) was used to characterize underlying inflammatory processes from 19 immune markers. Logistic regression with generalized estimating equations was used to evaluate associations between inflammatory processes and depressive symptoms stratified by HIV serostatus. Three EFA-identified inflammatory processes (EIPs) were identified. EIP-1 scores-described by soluble tumor necrosis factor receptor 2 (sTNF-R2), soluble interleukin-2 receptor α (sIL-2Rα), sCD27, B-cell activating factor, interferon γ-induced protein 10 (IP-10), soluble interleukin-6 receptor (sIL-6R), sCD14, and sGP130-were significantly associated with 9% higher odds of depressive symptoms in HIV+ participants (odds ratio = 1.09; 95% confidence interval: 1.03, 1.16) and 33% higher odds in HIV- participants (odds ratio = 1.33; 95% confidence interval: 1.09, 1.61). Findings suggest that immune activation might be involved in depression risk among both HIV+ and HIV- men who have sex with men., (© The Author(s) 2019. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2019
- Full Text
- View/download PDF
33. Sexual role and HIV-1 set point viral load among men who have sex with men.
- Author
-
Stansfield SE, Mittler JE, Gottlieb GS, Murphy JT, Hamilton DT, Detels R, Wolinsky SM, Jacobson LP, Margolick JB, Rinaldo CR, Herbeck JT, and Goodreau SM
- Subjects
- Adult, Biomarkers blood, Cohort Studies, HIV Infections transmission, Humans, Male, Middle Aged, Sexual Partners, HIV Infections blood, HIV Infections epidemiology, HIV-1 metabolism, Homosexuality, Male statistics & numerical data, Sexual Behavior statistics & numerical data, Viral Load statistics & numerical data
- Abstract
Background: HIV-1 set point viral load (SPVL) is a highly variable trait that influences disease progression and transmission risk. Men who are exclusively insertive (EI) during anal intercourse require more sexual contacts to become infected than exclusively receptive (ER) men. Thus, we hypothesize that EIs are more likely to acquire their viruses from highly infectious partners (i.e., with high SPVLs) and to have higher SPVLs than infected ERs., Methods: We used a one-generation Bernoulli model, a dynamic network model, and data from the Multicenter AIDS Cohort Study (MACS) to examine whether and under what circumstances MSM differ in SPVL by sexual role., Results: Both models predicted higher SPVLs in EIs than role versatile (RV) or ER men, but only in scenarios where longer-term relationships predominated. ER and RV men displayed similar SPVLs. EI men remained far less likely than ER men to become infected, however. When the MACS data were limited by some estimates of lower sex partner counts (a proxy for longer relationships), EI men had higher SPVLs; these differences were clinically relevant (>0.3 log
10 copies/mL) and statistically significant (p < 0.05)., Conclusions: Mode of acquisition may be an important aspect of SPVL evolution in MSM, with clinical implications., (Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF
34. Effect of marijuana smoking on pulmonary disease in HIV-infected and uninfected men: a longitudinal cohort study.
- Author
-
Lorenz DR, Uno H, Wolinsky SM, and Gabuzda D
- Abstract
Background: Lung disease is a common comorbidity in people with HIV/AIDS, independent of smoking status. The effects of marijuana smoking on risk of lung disease in HIV-infected individuals are unclear., Methods: In this prospective cohort study, we quantified lung disease risk among men enrolled in the Multicenter AIDS Cohort Study (MACS), a long-term observational cohort of HIV-infected and uninfected men who have sex with men. Eligible participants were aged ≥30 years with self-reported marijuana and tobacco smoking data from biannual study visits between 1996 and 2014. Pulmonary diagnoses were obtained from self-report and medical records. Analyses were performed using Cox models and Generalized Estimating Equations adjusted for tobacco smoking, CD4 T cell count, and other risk factors., Findings: 1,630 incident pulmonary diagnoses were reported among 1,352 HIV-seropositive and 1,352 HIV-seronegative eligible participants matched for race and baseline age (53,794 total person-visits, median follow-up 10.5 years). 27% of HIV-infected participants reported daily or weekly marijuana smoking for one or more years in follow-up, compared to 18% of uninfected participants (median 4·0 and 4·5 years daily/weekly use, respectively). HIV-infected participants had an increased likelihood of infectious or non-infectious pulmonary diagnoses compared to uninfected participants (33·2% vs. 21·5%, and 20·6% vs. 17·2%, respectively). Among HIV-infected participants, recent marijuana smoking was associated with increased risk of infectious pulmonary diagnoses and chronic bronchitis independent of tobacco smoking and other risk factors for lung disease (hazard ratio [95% confidence interval] 1·43 [1·09-1·86], and 1·54 [1·11-2·13], respectively); these risks were additive in participants smoking both substances. There was no association between marijuana smoking and pulmonary diagnoses in HIV-uninfected participants., Interpretation: In this longitudinal study, long-term marijuana smoking was associated with lung disease independent of tobacco smoking and other risk factors in HIV-infected individuals. These findings could be used to reduce modifiable risks of lung disease in high-risk populations., Competing Interests: Declaration of interests We declare no competing interests.
- Published
- 2019
- Full Text
- View/download PDF
35. Low T-cell subsets prior to development of virus-associated cancer in HIV-seronegative men who have sex with men.
- Author
-
Dutta A, Uno H, Lorenz DR, Wolinsky SM, and Gabuzda D
- Subjects
- Adult, CD4-CD8 Ratio, Case-Control Studies, Humans, Longitudinal Studies, Male, Middle Aged, Smoking, HIV Seronegativity immunology, Homosexuality, Male, Leukocyte Count, Neoplasms immunology, Neoplasms virology, T-Lymphocyte Subsets
- Abstract
Immunological parameters that influence susceptibility to virus-associated cancers in HIV-seronegative individuals are unclear. We conducted a case-control cohort study of immunological parameters associated with development of incident virus-associated cancers among 532 HIV-seronegative men who have sex with men (MSM) enrolled in the Multicenter AIDS Cohort Study (MACS) with median (IQR) 21 (8-26) years of follow-up. Thirty-two incident virus-associated cancers (anal cancer, non-Hodgkin lymphoma, liver cancer, other cancers with etiologies linked to human papillomavirus, Epstein-Barr virus, hepatitis B virus, or human herpesvirus-8) were identified among 3,408 HIV-seronegative men in the MACS during 1984-2010. Cases were matched for demographics, smoking, and follow-up to 500 controls without cancer. Mixed-effects and Cox regression models were used to examine associations between nadir or recent CD4, CD8, and white blood cell (WBC) counts or CD4:CD8 ratios and subsequent diagnosis of virus-associated cancers. Men with incident virus-associated cancers had lower CD4 and WBC counts over a 6-year window prior to diagnosis compared to men without cancer (p = 0.001 and 0.03, respectively). Low CD4 cell count and nadir, CD4 count-nadir differential, and CD4:CD8 ratio nadir were associated with increased 2-year risk of incident virus-associated cancers in models adjusted for demographics and smoking (hazard ratios 1.2-1.3 per 100 or 0.1 unit decrease, respectively; p < 0.01). Other associated factors included heavy smoking and past or current hepatitis B virus infection. These findings show that low CD4 cell counts, CD4 nadir, and CD4:CD8 cell ratios are independent predictors for subsequent risk of virus-associated cancers in HIV-seronegative MSM.
- Published
- 2018
- Full Text
- View/download PDF
36. Polymorphisms in Rhesus Macaque Tetherin Are Associated with Differences in Acute Viremia in Simian Immunodeficiency Virus Δ nef -Infected Animals.
- Author
-
Janaka SK, Tavakoli-Tameh A, Neidermyer WJ Jr, Serra-Moreno R, Hoxie JA, Desrosiers RC, Johnson RP, Lifson JD, Wolinsky SM, and Evans DT
- Subjects
- Amino Acid Sequence, Animals, Base Sequence, Cell Line, HEK293 Cells, Humans, Macaca mulatta, Polymorphism, Single Nucleotide genetics, Sequence Analysis, RNA, Simian Acquired Immunodeficiency Syndrome virology, Bone Marrow Stromal Antigen 2 genetics, Simian Acquired Immunodeficiency Syndrome genetics, Simian Immunodeficiency Virus genetics, Viral Load genetics, Viral Regulatory and Accessory Proteins genetics, Viremia veterinary
- Abstract
Tetherin (BST-2 or CD317) is an interferon-inducible transmembrane protein that inhibits virus release from infected cells. To determine the extent of sequence variation and the impact of polymorphisms in rhesus macaque tetherin on simian immunodeficiency virus (SIV) infection, tetherin alleles were sequenced from 146 rhesus macaques, including 68 animals infected with wild-type SIV
mac 239 and 47 animals infected with SIVmac 239Δ nef Since Nef is the viral gene product of SIV that counteracts restriction by tetherin, these groups afford a comparison of the effects of tetherin polymorphisms on SIV strains that are, and are not, resistant to tetherin. We identified 15 alleles of rhesus macaque tetherin with dimorphic residues at 9 positions. The relationship between these alleles and plasma viral loads was compared during acute infection, prior to the onset of adaptive immunity. Acute viremia did not differ significantly among the wild-type SIV-infected animals; however, differences in acute viral loads were associated with polymorphisms in tetherin among the animals infected with SIVΔ nef In particular, polymorphisms at positions 43 and 111 (P43 and H111 ) were associated with lower acute-phase viral loads for SIVΔ nef infection. These observations reveal extensive polymorphism in rhesus macaque tetherin, maintained perhaps as a consequence of variability in the selective pressure of diverse viral pathogens, and identify tetherin alleles that may have an inherently greater capacity to restrict SIV replication in the absence of Nef. IMPORTANCE As a consequence of ongoing evolutionary conflict with viral pathogens, tetherin has accumulated numerous species-specific differences that represent important barriers to the transmission of viruses between species. This study reveals extensive polymorphism in rhesus macaque tetherin and identifies specific alleles that are associated with lower viral loads during the first few weeks after infection with nef -deleted SIV. These observations suggest that the variable selective pressure of viral pathogens, in addition to driving the diversification of tetherin among species, also operates within certain species to maintain sequence variation in tetherin., (Copyright © 2018 American Society for Microbiology.)- Published
- 2018
- Full Text
- View/download PDF
37. Comprehensive innate immune profiling of chikungunya virus infection in pediatric cases.
- Author
-
Michlmayr D, Pak TR, Rahman AH, Amir ED, Kim EY, Kim-Schulze S, Suprun M, Stewart MG, Thomas GP, Balmaseda A, Wang L, Zhu J, Suaréz-Fariñas M, Wolinsky SM, Kasarskis A, and Harris E
- Subjects
- Adolescent, Animals, Cell Lineage genetics, Cell Lineage immunology, Chikungunya Fever transmission, Chikungunya Fever virology, Chikungunya virus immunology, Chikungunya virus pathogenicity, Child, Child, Preschool, Culicidae virology, Cytokines blood, Cytokines genetics, Dendritic Cells immunology, Gene Expression Regulation genetics, Gene Expression Regulation immunology, Humans, Infant, Infant, Newborn, Leukocytes, Mononuclear immunology, Leukocytes, Mononuclear virology, Lipopolysaccharide Receptors genetics, Lipopolysaccharide Receptors immunology, Monocytes immunology, Pediatrics, Receptors, IgG genetics, Receptors, IgG immunology, Sequence Analysis, RNA, Transcriptome immunology, Chikungunya Fever genetics, Chikungunya virus genetics, Immunity, Innate genetics, Transcriptome genetics
- Abstract
Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that causes global epidemics of debilitating disease worldwide. To gain functional insight into the host cellular genes required for virus infection, we performed whole-blood RNA-seq, 37-plex mass cytometry of peripheral blood mononuclear cells (PBMCs), and serum cytokine measurements of acute- and convalescent-phase samples obtained from 42 children naturally infected with CHIKV Semi-supervised classification and clustering of single-cell events into 57 sub-communities of canonical leukocyte phenotypes revealed a monocyte-driven response to acute infection, with the greatest expansions in "intermediate" CD14
++ CD16+ monocytes and an activated subpopulation of CD14+ monocytes. Increases in acute-phase CHIKV envelope protein E2 expression were highest for monocytes and dendritic cells. Serum cytokine measurements confirmed significant acute-phase upregulation of monocyte chemoattractants. Distinct transcriptomic signatures were associated with infection timepoint, as well as convalescent-phase anti-CHIKV antibody titer, acute-phase viremia, and symptom severity. We present a multiscale network that summarizes all observed modulations across cellular and transcriptomic levels and their interactions with clinical outcomes, providing a uniquely global view of the biomolecular landscape of human CHIKV infection., (© 2018 The Authors. Published under the terms of the CC BY 4.0 license.)- Published
- 2018
- Full Text
- View/download PDF
38. Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1.
- Author
-
Martin MP, Naranbhai V, Shea PR, Qi Y, Ramsuran V, Vince N, Gao X, Thomas R, Brumme ZL, Carlson JM, Wolinsky SM, Goedert JJ, Walker BD, Segal FP, Deeks SG, Haas DW, Migueles SA, Connors M, Michael N, Fellay J, Gostick E, Llewellyn-Lacey S, Price DA, Lafont BA, Pymm P, Saunders PM, Widjaja J, Wong SC, Vivian JP, Rossjohn J, Brooks AG, and Carrington M
- Subjects
- Adult, Cohort Studies, Female, Humans, Male, Middle Aged, Genetic Variation, HIV Infections genetics, HIV Infections immunology, HIV-1 immunology, HLA-B Antigens genetics, HLA-B Antigens immunology, Receptors, KIR3DL1 genetics, Receptors, KIR3DL1 immunology
- Abstract
HLA-B*57 control of HIV involves enhanced CD8+ T cell responses against infected cells, but extensive heterogeneity exists in the level of HIV control among B*57+ individuals. Using whole-genome sequencing of untreated B*57+ HIV-1-infected controllers and noncontrollers, we identified a single variant (rs643347A/G) encoding an isoleucine-to-valine substitution at position 47 (I47V) of the inhibitory killer cell immunoglobulin-like receptor KIR3DL1 as the only significant modifier of B*57 protection. The association was replicated in an independent cohort and across multiple outcomes. The modifying effect of I47V was confined to B*57:01 and was not observed for the closely related B*57:03. Positions 2, 47, and 54 tracked one another nearly perfectly, and 2 KIR3DL1 allotypes differing only at these 3 positions showed significant differences in binding B*57:01 tetramers, whereas the protective allotype showed lower binding. Thus, variation in an immune NK cell receptor that binds B*57:01 modifies its protection. These data highlight the exquisite specificity of KIR-HLA interactions in human health and disease.
- Published
- 2018
- Full Text
- View/download PDF
39. Increased T cell trafficking as adjunct therapy for HIV-1.
- Author
-
Fryer HR, Wolinsky SM, and McLean AR
- Subjects
- CD4 Lymphocyte Count methods, CD4-Positive T-Lymphocytes physiology, CD4-Positive T-Lymphocytes virology, Computer Simulation, HIV Infections virology, HIV-1 pathogenicity, HIV-1 physiology, Humans, Models, Theoretical, T-Lymphocytes physiology, Viral Load methods, Virus Latency physiology, Virus Replication physiology, Disease Reservoirs virology, HIV Infections therapy, Virus Replication drug effects
- Abstract
Although antiretroviral drug therapy suppresses human immunodeficiency virus-type 1 (HIV-1) to undetectable levels in the blood of treated individuals, reservoirs of replication competent HIV-1 endure. Upon cessation of antiretroviral therapy, the reservoir usually allows outgrowth of virus and approaches to targeting the reservoir have had limited success. Ongoing cycles of viral replication in regions with low drug penetration contribute to this persistence. Here, we use a mathematical model to illustrate a new approach to eliminating the part of the reservoir attributable to persistent replication in drug sanctuaries. Reducing the residency time of CD4 T cells in drug sanctuaries renders ongoing replication unsustainable in those sanctuaries. We hypothesize that, in combination with antiretroviral drugs, a strategy to orchestrate CD4 T cell trafficking could contribute to a functional cure for HIV-1 infection.
- Published
- 2018
- Full Text
- View/download PDF
40. Elevated HLA-A expression impairs HIV control through inhibition of NKG2A-expressing cells.
- Author
-
Ramsuran V, Naranbhai V, Horowitz A, Qi Y, Martin MP, Yuki Y, Gao X, Walker-Sperling V, Del Prete GQ, Schneider DK, Lifson JD, Fellay J, Deeks SG, Martin JN, Goedert JJ, Wolinsky SM, Michael NL, Kirk GD, Buchbinder S, Haas D, Ndung'u T, Goulder P, Parham P, Walker BD, Carlson JM, and Carrington M
- Subjects
- Alleles, CD4 Lymphocyte Count, Cohort Studies, HIV Infections drug therapy, HIV Infections genetics, HLA Antigens genetics, Humans, Ligands, NK Cell Lectin-Like Receptor Subfamily C antagonists & inhibitors, NK Cell Lectin-Like Receptor Subfamily C genetics, Protein Sorting Signals, Viremia immunology, HIV immunology, HIV Infections immunology, HLA Antigens metabolism, Killer Cells, Natural immunology, NK Cell Lectin-Like Receptor Subfamily C metabolism
- Abstract
The highly polymorphic human leukocyte antigen ( HLA ) locus encodes cell surface proteins that are critical for immunity. HLA-A expression levels vary in an allele-dependent manner, diversifying allele-specific effects beyond peptide-binding preference. Analysis of 9763 HIV-infected individuals from 21 cohorts shows that higher HLA-A levels confer poorer control of HIV. Elevated HLA-A expression provides enhanced levels of an HLA-A-derived signal peptide that specifically binds and determines expression levels of HLA-E, the ligand for the inhibitory NKG2A natural killer (NK) cell receptor. HLA-B haplotypes that favor NKG2A-mediated NK cell licensing (i.e., education) exacerbate the deleterious effect of high HLA-A on HIV control, consistent with NKG2A-mediated inhibition impairing NK cell clearance of HIV-infected targets. Therapeutic blockade of HLA-E:NKG2A interaction may yield benefit in HIV disease., (Copyright © 2017, American Association for the Advancement of Science.)
- Published
- 2018
- Full Text
- View/download PDF
41. Lorenzo-Redondo et al. reply.
- Author
-
Lorenzo-Redondo R, Fryer HR, Bedford T, Kim EY, Archer J, Pond SLK, Chung YS, Penugonda S, Chipman JG, Fletcher CV, Schacker TW, Malim MH, Rambaut A, Haase AT, McLean AR, and Wolinsky SM
- Published
- 2017
- Full Text
- View/download PDF
42. HLA-B*14:02-Restricted Env-Specific CD8 + T-Cell Activity Has Highly Potent Antiviral Efficacy Associated with Immune Control of HIV Infection.
- Author
-
Leitman EM, Willberg CB, Tsai MH, Chen H, Buus S, Chen F, Riddell L, Haas D, Fellay J, Goedert JJ, Piechocka-Trocha A, Walker BD, Martin J, Deeks S, Wolinsky SM, Martinson J, Martin M, Qi Y, Sáez-Cirión A, Yang OO, Matthews PC, Carrington M, and Goulder PJR
- Subjects
- Adult, CD8-Positive T-Lymphocytes, HIV Infections pathology, HIV Infections therapy, Humans, HIV Envelope Protein gp160 immunology, HIV Infections immunology, HIV-1 immunology, HLA-B14 Antigen immunology, Immunity, Cellular, Peptides immunology, gag Gene Products, Human Immunodeficiency Virus immunology
- Abstract
Immune control of human immunodeficiency virus type 1 (HIV) infection is typically associated with effective Gag-specific CD8
+ T-cell responses. We here focus on HLA-B*14, which protects against HIV disease progression, but the immunodominant HLA-B*14-restricted anti-HIV response is Env specific (ERYLKDQQL, HLA-B*14-EL9). A subdominant HLA-B*14-restricted response targets Gag (DRYFKTLRA, HLA-B*14-DA9). Using HLA-B*14/peptide-saporin-conjugated tetramers, we show that HLA-B*14-EL9 is substantially more potent at inhibiting viral replication than HLA-B*14-DA9. HLA-B*14-EL9 also has significantly higher functional avidity ( P < 0.0001) and drives stronger selection pressure on the virus than HLA-B*14-DA9. However, these differences were HLA-B*14 subtype specific, applying only to HLA-B*14:02 and not to HLA-B*14:01. Furthermore, the HLA-B*14-associated protection against HIV disease progression is significantly greater for HLA-B*14:02 than for HLA-B*14:01, consistent with the superior antiviral efficacy of the HLA-B*14-EL9 response. Thus, although Gag-specific CD8+ T-cell responses may usually have greater anti-HIV efficacy, factors independent of protein specificity, including functional avidity of individual responses, are also critically important to immune control of HIV. IMPORTANCE In HIV infection, although cytotoxic T lymphocytes (CTL) play a potentially critical role in eradication of viral reservoirs, the features that constitute an effective response remain poorly defined. We focus on HLA-B*14, unique among HLAs associated with control of HIV in that the dominant CTL response is Env specific, not Gag specific. We demonstrate that Env-specific HLA-B*14-restricted activity is substantially more efficacious than the subdominant HLA-B*14-restricted Gag response. Env immunodominance over Gag and strong Env-mediated selection pressure on HIV are observed only in subjects expressing HLA-B*14:02, and not HLA-B*14:01. This reflects the increased functional avidity of the Env response over Gag, substantially more marked for HLA-B*14:02. Finally, we show that HLA-B*14:02 is significantly more strongly associated with viremic control than HLA-B*14:01. These findings indicate that, although Gag-specific CTL may usually have greater anti-HIV efficacy than Env responses, factors independent of protein specificity, including functional avidity, may carry greater weight in mediating effective control of HIV., (Copyright © 2017 Leitman et al.)- Published
- 2017
- Full Text
- View/download PDF
43. Long-term nitrite inhalant exposure and cancer risk in MSM.
- Author
-
Dutta A, Uno H, Holman A, Lorenz DR, Wolinsky SM, and Gabuzda D
- Subjects
- Adult, HIV Infections complications, Herpesviridae Infections complications, Homosexuality, Male, Humans, Male, Middle Aged, Papillomavirus Infections complications, Prospective Studies, Risk Assessment, Drug Utilization, Illicit Drugs adverse effects, Neoplasms epidemiology, Nitrites adverse effects
- Abstract
Objectives: Nitrite inhalants (poppers) are commonly used recreational drugs among MSM and were previously associated with elevated rates of high-risk sexual behavior, HIV and human herpesvirus type 8 (HHV-8) seroconversion, and transient immunosuppressive effects in experimental models. Whether long-term popper use is associated with cancer risk among MSM in the HAART era is unclear., Design: Prospective cohort study of cancer risk in 3223 HIV-infected and uninfected MSM in the Multicenter AIDS Cohort Study from 1996-2010., Methods: Poisson regression models were used to examine the association between heavy popper use (defined as daily or weekly use for at least 1 year) and risk of individual cancers or composite category of virus-associated cancers., Results: Among all participants, heavy popper use was not associated with increased risk of any individual cancers. Among HIV-uninfected men aged 50-70, heavy popper use was associated with increased risk of virus-associated cancer with causes linked to human papillomavirus, HHV-8, and Epstein-Barr virus in models adjusted for demographics, number of sexual partners, immunological parameters (CD4 cell counts or CD4/CD8 ratios), and hepatitis B and C viruses [incidence rate ratio (IRR), 95% confidence interval (CI) 3.24, 1.05-9.96], or sexually transmitted infections (IRR 3.03, 95% CI, 1.01-9.09), as was cumulative use over a 5-year period (IRR 1.012, 95% CI 1.003-1.021; P = 0.007). There was no significant association between heavy popper use and virus-associated cancer in HIV-infected men., Conclusions: Long-term heavy popper use is associated with elevated risk of some virus-associated cancers with causes related to human papillomavirus, HHV-8, and Epstein-Barr virus infections in older HIV-uninfected MSM independent of sexual behavior and immunological parameters.
- Published
- 2017
- Full Text
- View/download PDF
44. Lipid Profiles and APOE4 Allele Impact Midlife Cognitive Decline in HIV-Infected Men on Antiretroviral Therapy.
- Author
-
Mukerji SS, Locascio JJ, Misra V, Lorenz DR, Holman A, Dutta A, Penugonda S, Wolinsky SM, and Gabuzda D
- Subjects
- Age Factors, Aged, Antiretroviral Therapy, Highly Active, Biomarkers, Cognitive Dysfunction diagnosis, Disease Susceptibility, Female, Follow-Up Studies, Genotype, HIV Infections drug therapy, Humans, Male, Mental Status and Dementia Tests, Middle Aged, Risk Factors, Alleles, Apolipoprotein E4 genetics, Cognitive Dysfunction blood, Cognitive Dysfunction etiology, HIV Infections complications, HIV Infections genetics, Lipids blood
- Abstract
Background: Dyslipidemia and apolipoprotein E4 (APOE ϵ4) allele are risk factors for age-related cognitive decline, but how these risks are modified by human immunodeficiency virus (HIV) infection is unclear., Methods: In a longitudinal nested study from the Multicenter AIDS Cohort Study, 273 HIV type 1-infected (HIV(+)) men aged 50-65 years with baseline HIV RNA <400 copies/mL and on continuous antiretroviral therapy (ART) in ≥95% of follow-up visits were matched by sociodemographic variables to 516 HIV-uninfected (HIV(-)) controls. The association between lipid markers (total cholesterol, low-density lipoprotein cholesterol [LDL-C], high-density lipoprotein cholesterol [HDL-C], and triglycerides), APOE genotype, and cognitive decline in HIV infection was examined using mixed-effects models., Results: The median baseline age of participants was 51, 81% were white, and 89% had education >12 years. HIV(+) men had similar baseline total cholesterol and LDL-C, but lower HDL-C and higher triglycerides than controls (P < .001). Higher total cholesterol and LDL-C were associated with faster rates of cognitive decline (P < .01), whereas higher HDL-C attenuated decline (P = .02) in HIV(+) men. In HIV(+) men with elevated cholesterol, statin use was associated with a slower estimated rate of decline (P = .02). APOE ϵ4 genotype accelerated cognitive decline in HIV(+) but not HIV(-) men (P = .01), with trajectories diverging from HIV(-) ε4 carriers after age 50. Total cholesterol levels did not modify the association of ϵ4 genotype with decline (P = .9)., Conclusions: Elevated cholesterol and APOE ϵ4 genotype are independent risk factors for cognitive decline in ART-adherent HIV(+) men aged >50 years. Treatment of dyslipidemia may be an effective strategy to reduce cognitive decline in older HIV(+) individuals., (© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America.)
- Published
- 2016
- Full Text
- View/download PDF
45. Identification of Siglec-1 null individuals infected with HIV-1.
- Author
-
Martinez-Picado J, McLaren PJ, Erkizia I, Martin MP, Benet S, Rotger M, Dalmau J, Ouchi D, Wolinsky SM, Penugonda S, Günthard HF, Fellay J, Carrington M, Izquierdo-Useros N, and Telenti A
- Subjects
- Adult, Alleles, CD4-Positive T-Lymphocytes metabolism, Cell Lineage, Dendritic Cells metabolism, Disease Progression, Exome, Exons, Female, Genetics, Population, Genotype, HIV-1, Heterozygote, Homozygote, Humans, Leukocytes, Mononuclear metabolism, Longitudinal Studies, Male, Middle Aged, Prospective Studies, Switzerland, United States, HIV Infections genetics, Sialic Acid Binding Ig-like Lectin 1 genetics
- Abstract
Siglec-1/CD169 is a myeloid-cell surface receptor critical for HIV-1 capture and infection of bystander target cells. To dissect the role of SIGLEC1 in natura, we scan a large population genetic database and identify a loss-of-function variant (Glu88Ter) that is found in ∼1% of healthy people. Exome analysis and direct genotyping of 4,233 HIV-1-infected individuals reveals two Glu88Ter homozygous and 97 heterozygous subjects, allowing the analysis of ex vivo and in vivo consequences of SIGLEC1 loss-of-function. Cells from these individuals are functionally null or haploinsufficient for Siglec-1 activity in HIV-1 capture and trans-infection ex vivo. However, Siglec-1 protein truncation does not have a measurable impact on HIV-1 acquisition or AIDS outcomes in vivo. This result contrasts with the known in vitro functional role of Siglec-1 in HIV-1 trans-infection. Thus, it provides evidence that the classical HIV-1 infectious routes may compensate for the lack of Siglec-1 in fuelling HIV-1 dissemination within infected individuals.
- Published
- 2016
- Full Text
- View/download PDF
46. Persistent HIV-1 replication maintains the tissue reservoir during therapy.
- Author
-
Lorenzo-Redondo R, Fryer HR, Bedford T, Kim EY, Archer J, Pond SLK, Chung YS, Penugonda S, Chipman J, Fletcher CV, Schacker TW, Malim MH, Rambaut A, Haase AT, McLean AR, and Wolinsky SM
- Subjects
- Anti-HIV Agents administration & dosage, Anti-HIV Agents pharmacology, Anti-HIV Agents therapeutic use, Carrier State blood, Drug Resistance, Viral drug effects, HIV Infections blood, HIV-1 drug effects, HIV-1 genetics, HIV-1 isolation & purification, Haplotypes drug effects, Humans, Lymph Nodes drug effects, Lymph Nodes virology, Models, Biological, Molecular Sequence Data, Phylogeny, Selection, Genetic drug effects, Sequence Analysis, DNA, Spatio-Temporal Analysis, Time Factors, Carrier State drug therapy, Carrier State virology, HIV Infections drug therapy, HIV Infections virology, HIV-1 growth & development, Viral Load drug effects, Virus Replication drug effects
- Abstract
Lymphoid tissue is a key reservoir established by HIV-1 during acute infection. It is a site associated with viral production, storage of viral particles in immune complexes, and viral persistence. Although combinations of antiretroviral drugs usually suppress viral replication and reduce viral RNA to undetectable levels in blood, it is unclear whether treatment fully suppresses viral replication in lymphoid tissue reservoirs. Here we show that virus evolution and trafficking between tissue compartments continues in patients with undetectable levels of virus in their bloodstream. We present a spatial and dynamic model of persistent viral replication and spread that indicates why the development of drug resistance is not a foregone conclusion under conditions in which drug concentrations are insufficient to completely block virus replication. These data provide new insights into the evolutionary and infection dynamics of the virus population within the host, revealing that HIV-1 can continue to replicate and replenish the viral reservoir despite potent antiretroviral therapy.
- Published
- 2016
- Full Text
- View/download PDF
47. Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load.
- Author
-
McLaren PJ, Coulonges C, Bartha I, Lenz TL, Deutsch AJ, Bashirova A, Buchbinder S, Carrington MN, Cossarizza A, Dalmau J, De Luca A, Goedert JJ, Gurdasani D, Haas DW, Herbeck JT, Johnson EO, Kirk GD, Lambotte O, Luo M, Mallal S, van Manen D, Martinez-Picado J, Meyer L, Miro JM, Mullins JI, Obel N, Poli G, Sandhu MS, Schuitemaker H, Shea PR, Theodorou I, Walker BD, Weintrob AC, Winkler CA, Wolinsky SM, Raychaudhuri S, Goldstein DB, Telenti A, de Bakker PI, Zagury JF, and Fellay J
- Subjects
- Adult, Alleles, Amino Acids genetics, Chromosomes, Human, Pair 3 genetics, Genome-Wide Association Study, HLA-B Antigens genetics, Humans, Inheritance Patterns genetics, Physical Chromosome Mapping, Receptors, CCR5 genetics, Genetic Predisposition to Disease, HIV-1 genetics, Host-Pathogen Interactions genetics, Polymorphism, Single Nucleotide genetics, Viral Load genetics
- Abstract
Previous genome-wide association studies (GWAS) of HIV-1-infected populations have been underpowered to detect common variants with moderate impact on disease outcome and have not assessed the phenotypic variance explained by genome-wide additive effects. By combining the majority of available genome-wide genotyping data in HIV-infected populations, we tested for association between ∼8 million variants and viral load (HIV RNA copies per milliliter of plasma) in 6,315 individuals of European ancestry. The strongest signal of association was observed in the HLA class I region that was fully explained by independent effects mapping to five variable amino acid positions in the peptide binding grooves of the HLA-B and HLA-A proteins. We observed a second genome-wide significant association signal in the chemokine (C-C motif) receptor (CCR) gene cluster on chromosome 3. Conditional analysis showed that this signal could not be fully attributed to the known protective CCR5Δ32 allele and the risk P1 haplotype, suggesting further causal variants in this region. Heritability analysis demonstrated that common human genetic variation-mostly in the HLA and CCR5 regions-explains 25% of the variability in viral load. This study suggests that analyses in non-European populations and of variant classes not assessed by GWAS should be priorities for the field going forward.
- Published
- 2015
- Full Text
- View/download PDF
48. Bioinformatic analysis of neurotropic HIV envelope sequences identifies polymorphisms in the gp120 bridging sheet that increase macrophage-tropism through enhanced interactions with CCR5.
- Author
-
Mefford ME, Kunstman K, Wolinsky SM, and Gabuzda D
- Subjects
- Amino Acid Sequence, Brain metabolism, Computational Biology, HIV Envelope Protein gp120 metabolism, HIV Infections genetics, HIV Infections virology, HIV-1 chemistry, HIV-1 genetics, Humans, Macrophages metabolism, Molecular Sequence Data, Polymorphism, Single Nucleotide, Protein Binding, Protein Structure, Secondary, Receptors, CCR5 genetics, Sequence Alignment, Brain virology, HIV Envelope Protein gp120 chemistry, HIV Envelope Protein gp120 genetics, HIV Infections metabolism, HIV-1 physiology, Macrophages virology, Receptors, CCR5 metabolism, Viral Tropism
- Abstract
Macrophages express low levels of the CD4 receptor compared to T-cells. Macrophage-tropic HIV strains replicating in brain of untreated patients with HIV-associated dementia (HAD) express Envs that are adapted to overcome this restriction through mechanisms that are poorly understood. Here, bioinformatic analysis of env sequence datasets together with functional studies identified polymorphisms in the β3 strand of the HIV gp120 bridging sheet that increase M-tropism. D197, which results in loss of an N-glycan located near the HIV Env trimer apex, was detected in brain in some HAD patients, while position 200 was estimated to be under positive selection. D197 and T/V200 increased fusion and infection of cells expressing low CD4 by enhancing gp120 binding to CCR5. These results identify polymorphisms in the HIV gp120 bridging sheet that overcome the restriction to macrophage infection imposed by low CD4 through enhanced gp120-CCR5 interactions, thereby promoting infection of brain and other macrophage-rich tissues., (Copyright © 2015 Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
49. The association between APOL1 risk alleles and longitudinal kidney function differs by HIV viral suppression status.
- Author
-
Estrella MM, Li M, Tin A, Abraham AG, Shlipak MG, Penugonda S, Hussain SK, Palella FJ Jr, Wolinsky SM, Martinson JJ, Parekh RS, and Kao WH
- Subjects
- Alleles, Antiretroviral Therapy, Highly Active, Apolipoprotein L1, Cohort Studies, Follow-Up Studies, Genetic Predisposition to Disease, Genotype, HIV genetics, HIV Infections drug therapy, Humans, Male, RNA, Viral blood, Risk Factors, Viral Load, Black or African American genetics, Apolipoproteins genetics, Glomerular Filtration Rate genetics, HIV physiology, HIV Infections physiopathology, HIV Infections virology, Kidney physiopathology, Lipoproteins, HDL genetics
- Abstract
Background: Existing data suggest that human immunodeficiency virus (HIV)-infected African Americans carrying 2 copies of the APOL1 risk alleles have greater risk of kidney disease than noncarriers. We sought to determine whether HIV RNA suppression mitigates APOL1-related kidney function decline among African Americans enrolled in the Multicenter AIDS Cohort Study., Methods: We genotyped HIV-infected men for the G1 and G2 risk alleles and ancestry informative markers. Mixed-effects models were used to estimate the annual rate of estimated glomerular filtration rate (eGFR) decline, comparing men carrying 2 (high-risk) vs 0-1 risk allele (low-risk). Effect modification by HIV suppression status (defined as HIV type 1 RNA level <400 copies/mL for >90% of follow-up time) was evaluated using interaction terms and stratified analyses., Results: Of the 333 African American men included in this study, 54 (16%) carried the APOL1 high-risk genotype. Among HIV-infected men with unsuppressed viral loads, those with the high-risk genotype had a 2.42 mL/minute/1.73 m(2) (95% confidence interval [CI], -3.52 to -1.32) faster annual eGFR decline than men with the low-risk genotype. This association was independent of age, comorbid conditions, baseline eGFR, ancestry, and HIV-related factors. In contrast, the rate of decline was similar by APOL1 genotype among men with sustained viral suppression (-0.16 mL/minute/1.73 m(2)/year; 95% CI, -.59 to .27; P for interaction <.001)., Conclusions: Unsuppressed HIV-infected African Americans with the APOL1 high-risk genotype experience an accelerated rate of kidney function decline; HIV suppression with antiretroviral therapy may reduce these deleterious renal effects., (© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2015
- Full Text
- View/download PDF
50. Human metapneumovirus infection in chimpanzees, United States.
- Author
-
Slater OM, Terio KA, Zhang Y, Erdman DD, Schneider E, Kuypers JM, Wolinsky SM, Kunstman KJ, Kunstman J, Kinsel MJ, and Gamble KC
- Subjects
- Animals, Antibodies, Viral blood, Antibodies, Viral immunology, Ape Diseases diagnosis, Chicago epidemiology, Disease Outbreaks, Female, Humans, Male, Public Health Surveillance, Respiratory Mucosa pathology, Respiratory Mucosa virology, Seroepidemiologic Studies, United States epidemiology, Zoonoses epidemiology, Zoonoses virology, Ape Diseases epidemiology, Ape Diseases virology, Metapneumovirus classification, Metapneumovirus genetics, Metapneumovirus immunology, Metapneumovirus isolation & purification, Paramyxoviridae Infections veterinary
- Abstract
Zoonotic disease transmission and infections are of particular concern for humans and closely related great apes. In 2009, an outbreak of human metapneumovirus infection was associated with the death of a captive chimpanzee in Chicago, Illinois, USA. Biosecurity and surveillance for this virus in captive great ape populations should be considered.
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.